Isolated tumor necrosis factor receptor releasing enzyme, comopsitions comprising the enzyme and met

专利摘要:
The present invention relates to a method of indirectly regulating TNF activity by modulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, TRRE activity is adjusted locally at the site of the condition to be treated. In diseases associated with high levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amount sufficient to reduce local levels of TNF. In diseases such as cancer where increased levels of TNF are beneficial, the level of TRRE is reduced at the disease site.
公开号:KR20000053073A
申请号:KR1019990703993
申请日:1997-11-05
公开日:2000-08-25
发明作者:그랜저게일에이.；가타나가데츠야
申请人:더 리젠츠 오브 더 유니버시티 오브 캘리포니아；
IPC主号:

专利说明:

Isolated tumor necrosis factor receptor releasing enzyme, composition comprising the enzyme and method of using the same
Tumor necrosis factor (TNF or TNF-α) and lymphotoxin (LT or TNF-β) are related cytokines that share 40 percent amino acid (AA) sequence homology. Old (1987) Nature 330: 602-603. These cytokines are released mainly by macrophages, monocytes and natural killer (NK) cells in response to a broad immune response. Gorton and Galli (1990) Nature 346: 274-276; And Dubravec et al (1990) Proc. Natl. Acad. Sci. USA 87: 6758-6761. Although initially developed as a drug to induce tumor bleeding necrosis, these cytokines have been shown to play an essential role in both the induction and effector stages of immune response and inflammation. Both cytokines include (i) vascular thrombosis and tumor necrosis; (ii) inflammation; (iii) activation of macrophages and Neutrophil; (iv) leukocytosis; It causes a wide range of effects on ex vivo cells and tissues in vivo, including (v) apoptosis and (vi) shock. Beretz et al. (1990) Biorheology 27: 455-460; Driscoll (1994) Exp. Lung Res. 20: 473-490; Ferrante (1992) Immunol. Ser. 57: 417-436; Golstein et al. (1991) Immunol. Rev. 121: 29-65; And van der Poll and Lowry (1995) Shock 3: 1-12. For a review of the mechanism of action of TNF, see Massague (1996) Cell 85: 947-950. TNF has been associated with various disease states including various forms of cancer, arthritis, psoriasis, endotoxin shock, sepsis, autoimmune diseases, infections, obesity and cachexia. Attempts have been made to alter the course of the disease with varying degrees of success by treating patients with TNF inhibitors. For example, oxpentifylline did not alter the course of Crohn's disease, a chronic inflammatory bowel disease. Bauditz et al. (1997) Gut 40: 470-4. However, the TNF inhibitor dexanabinol provided protection against TNF after traumatic brain injury. Shohami et al. (1997) J. Neuroimmun. 72: 169-77.
Human TNFs and LTs mediate their biological activity in both cells and tissues by specifically binding to two, distinct or related glycoprotein plasma membrane receptors of 55 kDa and 75 kDa (p55 and p75 TNF-R, respectively). Holtmann and Wallach (1987) J. Immunol. 139: 151-153. Both receptors share 28 percent AA sequence homology in their extracellular domain, which consists of four repeating cysteine rich regions. Tartaglia and Goeddel (1992) Immunol. Today 13: 151-153. However, receptors lack significant AA sequence homology in their intracellular domains. Dembic et al. (1990) Cytokine 2: 231-237. Due to this difference, they transduce other signals and in turn exert various functions.
Recent studies have shown that most known cellular TNF responses, including cytotoxicity and induction of several genes, are due to p55 TNF-R activation. Engelmann et al. (1990) J. Biol. Chem. 265: 1531-1536; Shalaby et al. (1990) J. Exp. Med. 172: 1517-1520; And Tartaglia et al. (1991) Proc. Natl. Acad. Sci. USA 88: 9292-9296. In addition, the p55 receptor controls early acute graft-versus-host disease. Speiser et al. (1997) J. Immun. 158: 5185-90. In contrast, information on the biological activity of p75 TNF-R is limited. This receptor shares some activities with p55 TNF-R and is specifically involved in regulating the proliferation and secretion of cytokines by T cells. Shalaby et al. (1990); And Gehr et al. (1992) J. Immunol. 149: 911-917. Both belong to a family of constantly increasing membrane receptors, including low-affinity neuronal growth factor receptor (LNGF-R), FAS antigen, CD27, CD30 (Ki-1), CD40 (gp50) and OX40. Cosman (1994) Stem Cells (Dayt.) 12: 440-455; Meakin and Shooter (1992) Trends Neurosci. 15: 323-331; Grell et al. (1994) Eruo. J. Immunol. 24: 2563-2566; Moller et al. (1994) Int. J. Cancer 57: 371-377; Hintzen et al. (1994) J. Immunol. 152: 1762-1773; Smith et al. (1993) Cell 73: 1349-1360; Corcoran et al. (1994) Eur. J. Biochem 223: 831-840; And Baum et al. (1994) EMBO J. 13: 3992-4001.
All these receptors share a repeating pattern of cysteine rich domains in their extracellular domain. Depending on the pleiotropic activity of TNF and LT, most human cells express low levels (2,000 to 10,000 receptors / cell) of both TNF-Rs simultaneously. Brockhaus et al. (1990) Proc. Natl. Acad. Sci. US 87: 3127-3131. Expression of TNF-R in both lymphoid and nonlymphoid cells is characterized by bacterial lipopolysaccharide (LRS), phorbol myristate acetate (PMA; protein kinase C activator), interleukin-1 (IL-1), interferon-gamma Up and down regulation by many other agents such as (IFN- [gamma]) and IL-2. Gatanaga et al. (1991) Cell Immunol. 138: 1-10: Yui et al. (1994) Placenta. 15: 819-835; And Dett et al. (1991) J. Immunol. 146: 1522-1526. Although expressed at different rates, each receptor binds to TNF and LT with equally high affinity. Brockhaus et al. (1990); And Loetscher et al. (1990) J. Biol. Chem. 265: 20131-20138. Initial studies have shown that complexes of human TNF and TNF-R form on cell membranes, internalize globally and then degrade or recycle. Armitage (1994) Curr. Opin. Immunol. 6: 407-413: and Fiers (1991) FEBS Lett. 285: 199-212.
TNF binding protein (TNF-BP) was originally identified in the serum and urine of fever patients, individuals with renal failure, cancer patients, and certain healthy individuals. Seckinger et al. (1998) J. Exp. Med. 167: 1511-1516; Engelmann et al. (1989) J. Biol. Chem 264: 11974-11980; Seckinger et al. (1989) J. Biol. Chem. 264: 11966-11973; Peetre et al. (1988) Eur. J. Haematol. 41: 414-419; Olsson et al. (1989) Eur. J. Haematol. 42: 270-275; Gatanaga et al. (1990a) Lymphokine Res. 9: 225-229; And Gatanaga et al. (1990b) Proc. Natl. Acad. Sci USA 87: 8781-8784. In fact, human brain and ovarian tumors produced high serum levels of TNF-BP. Gatanaga et al. (1990a); And Gatanaga et al. (1990b). These molecules were then purified, characterized and cloned in other studies. Gatanaga et al. (1990b); Olsson et al. (1989); Schall et al. (1990) Cell 61: 361-370; Nophar et al. (1990) EMBO J. 9: 3269-3278; Himmler et al. (1990) DNA Cell Biol. 9: 705-715; Loetscher et al. (1990) Cell 61: 351-359; And Smith et al. (1990) Science 248: 10 19-1023. These proteins have been proposed for use in treating endotoxin shock. Mohler et al. (1993) J. Immunol. 151: 1548-1561; Porat et al. (1995) Crit. Care Med 23: 1080-1089; Fisher et al. (1996) N. Engl. J. Med 334: 1697-1702; Fenner (1995) Z. Rheumarol. 54: 158-164; And Jin et al. (1994) J. Infect. Dis. 170: 1323-1326.
Human TNF-BP consists of 30kDa and 40kDa proteins found to be identical to the extracellular domains of p55 and p75 TNF-R N-terminus, respectively. 30 kDa and 40 kDa TNF-BP are therefore also referred to as soluble p55 and p75 TNF-R, respectively. The study of these proteins has been facilitated by the availability of human recombinant 30kDa and 40kDa TNF-BP and antibodies that specifically recognize each form and allow quantification by immunoassay. Heller et al. (1990) Proc. Natl. Acad. Sci. USA 87: 6151-6155: US Patant No. 5,395,760; EP 418,014; And Grosen et al. (1993) Gynecol. Oncol. 50: 68-77. X-ray structural studies demonstrated that the TNF trimer binds to three soluble TNF-R (sTNF-R) molecules and that the complex can no longer interact with TNF-R. Banner et al. (1993) Cell 73: 431-445. However, the binding of trimers to sTNF-R is reversible and these reactants do not change as a result of complex formation. At high molar ratios of sTNF-R to TNF, both recombinant and native human sTNF-R are potent inhibitors of TNF / LT biological activity both in vivo and ex vivo. Gatanaga et al. (1990b); Ashkenazi et al. (1991) Proc. Natl. Acad. Sci. US 88: 10535-10539; Lesslaur et al. (1991) Eur. J. Immunol. 21: 2883-2886; Olsson et al. (1992) Eur. J. Haematol. 48: 1-9; And Kohno et al. (1990) Proc. Natl. Acad. Sci. USA 87: 8331-8335.
Increased levels of TNF-R are also associated with clinical sepsis (septic peritonitis), HIV-1 infection, and other inflammatory conditions. Kalinkovich et al. (1995) J. Interferon and Cyto. Res. 15: 749-757; Calvano et al. (1996) Arch Surg. 131: 434-437; and Etrel et al. (1994) Arch. Surg. 129: 1330-1337. Sepsis and septic shock harm thousands of patients each year and are essentially incurable. This fatal symptom is mainly caused by lipopolysaccharide (LPS) from gram negative bacteria and superantigens from gram positive bacteria. Clinical symptoms are mainly initiated by the release of endogenous mediators such as TNF from activated lymphoid cells. TNF induces the production of numerous other cytokines, including IL-1, gamma-interferon, IL-8 and IL-6. These cytokines, along with other factors, promote the clinical symptoms of shock. Recombinant human sTNF-R is currently being tested in clinical trials to block TNF / LT activity in patients with septic shock and other conditions where TNF and LT are considered etiological. Van Zee et al. (1992) Proc. Natl. Acad. Sci. USA 89: 4845-4849. Balb / c mice, the main animal model, and many techniques were used to test the effects of TNF modulators and other therapies on septic peritonitis. Jin et al. (1994) J. Infect Dis. 170: 1323-1326; Mohler et al. (1993) J. Immunol. 151: 1548-1561; Porat et al. (1995) Crit. Care Med. 23: 1080-1089; and Echtenacher et al. (1996) Nature 381: 75-77. Lipopolysaccharide induced shock has been shown to be improved by double inhibitors of FR 167653, IL-1 and TNF production. Yamamoto et al. (1997) Eur. J. Pharmacol. 327: 169-174.
Attempts have been made to ameliorate the adverse effects of TNF by treatment with other proteins that bind to TNF, such as TNF receptors treated or modified with monoclonal antibodies against TNF. Patients with sepsis or septic shock were treated with anti-TNF antibodies. Salat et al. (1997) Shock 6: 233-7. Some improvements in the clinical and histopathological signs of Crohn's disease have been provided by treatment with anti-TNF antibodies. Neurath et al. (1997) Eur. J. Immun. 27: 1743-50; van Deventer et al. (1997) Pharm. World Sci. 19: 55-9: van Hogezand et al. (1997) Scand. J. Gastro. 223: 105-7: and Stack et al. (1997) Lancer 349: 521-4. In the treatment of experimental autoimmune encephalitis (EAE), an animal model of human disease multiple sclerosis (MS), treatment with TNF-R fusion protein prevents disease and concomitant demyelination and the possible use of this treatment in MS patients. Suggest. Klinkert et al. (1997) J. Neuroimmun 72: 163-8. In patients with sepsis or septic shock, coagulation or fibrin lysis systems were not affected by anti-TNF antibodies. Satal et al. (1996) Shock 6: 233-7.
Modulation of TNF expression is being tested in the treatment of endotoxin shock. Mohler et al. (1994) Nature 370: 218-220. Modulation of TNF-R activity is also approached by the use of peptides that intracellularly bind to receptors or other components in the process for preventing receptor shedding. PCT Patent Publications: WO 95/31544, WO 95/33051; And WO 96/01642. Modulation of TNF-R activity is also presumed to be possible by interfering with the binding of peptides to TNF-R and signal transduction induced by TNF. European Patent Application EP 568 925.
Low levels of sTNF-R were found in normal individual serum, while high levels were found in the serum of patients with chronic inflammation, infections, renal failure and various forms of cancer. Aderka et al. (1992) Lymphokine Cytokine Res. 11: 157-159; Olsson et al. (1993) Eur. Cytokine Netw. 4: 169-180; Diez-Ruiz et al. (1995) Eur. J. Haematol. 54: 1-8; van Deuren (1994) Eur. J. Clin. Microbiol. Infect. Dis. 13 Suppl. 1: S12-6; Lambert et al. (1994) Nephrol. Dial. Transplant. 9: 1791-1796; Halwachs et al. (1994) Clin Investig. 72: 473-476; Gatanaga et al. (1990a); And Gatanaga et al. (1990b). Serum levels of sTNF-R rise within minutes after intravenous injection of human recombinant TNF or IL-2 in human cancer patients and remain high for 7-8 hours. Aderka et al. (1991) Cancer Res. 51: 5602-5607; And Miles et al. (1992) Br. J. Cancer 66: 1195-1199. In contrast, serum sTNF-R levels are chronically elevated in cancer patients and remain at high levels for many years. Grosen et al. (1993). It is evident that sTNF-R is a natural inhibitor of these cytokines and regulates their biological activity after secretion. Fusion proteins consisting of sTNF-R linked to portions of human IgG I have also been developed to treat rheumatoid arthritis and septic shock. Moreland et al. (1997) N. Eng. J. Med. 337: 141-7; Abraham et al. (1997) JAMA 277: 1531-8.
New evidence has yielded information on the regulation of cytokines secreted. Evidence indicates that cells release molecules that are similar or have binding sites for specific membrane receptors.
Massague and Pandiella (1993) Annu. Rev. Biochem. 62: 515-541; And Rose-John and Heinrich (1994) Biochem. J. 300: 281-290. These soluble forms specifically bind to cytokines and inactivate cytokines by steric inhibition at appropriate molar ratios. Therefore, this is a common phenomenon leading to the regulation of cytokine and membrane antigens.
Remarkably, in addition to TNF-R, several types of membrane molecules have both soluble and membrane forms, which include (i) cytokine receptors such as IL-1R, IL-2R, IL-4R, IL -5R, IL-6R, IL-7R, IL-9R, granulocyte-colony stimulator-R (G-CSF-R), granulocyte-macrophage-colony stimulator-R (GM-CSF-R), transformation Growth factor-β-R (TGFβ-R), platelet induced growth factor-R (PDGF-R), and epidermal growth factor-R (EGF-R); (ii) growth factors such as TNF- (pro-TNF-I), TGF-I, and CSF-I; (iii) adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1 / CD54) and vascular cell membrane adhesion molecules (VCAM-1 / CD106); (iv) TNF-R / NGF-R superfamily, such as LNGF-R, CD27, CD30, and CD40; And (v) other membrane proteins such as transferrin receptors, CD14 (receptors for LPS and LPS binding proteins), CD16 (Fcγ RIII), and CD23 (low affinity receptors for IgE). Colotta et al. (1993) Science 261: 472-475; Baran et al. (1988) J. Immunol. 141: 539-546; Mosley et al (1989) Cell 59: 335-348; Takaki et al. (1990) EMBO J. 9: 4367-4374: Novick et al. (1989) J. Exp. Med. 170: 1409-1414; Goodwin et al. (1990) Cell 60: 941-951; Renauld et al. (1992) Proc. Natl. Acad. Sci. USA 89: 5690-5694; Fukunaga et al. (1990) Proc. Natl. Acad. Sci. USA 87: 8702-8706; Raines et al. (1991) Proc. Natl. Acad. Sci. USA 88: 8203-8207; Lopez-Casillas et al. (1991) Cell 67: 785-795; Tiesman and Hart (1993) J. Biol. Chem. 268: 9621-9628; Khire et al. (1990) Febs. Lett. 272: 69-72: Kriegler et al. (1988) Cell 53: 45-53; Pandiella and Massague (1991) Proc. Natl. Acad. Sci. USA 88: 1726-1730; Stein et al. (1991) Oncogene 6: 601-605; Seth et al. (1991) Lancet 338: 83-84; Hahne et al. (1994) Eur. J. Immunol. 24: 421-428; Zupan et al. (1989) J. Biol. Chem. 246: 11714-11720: Loenen et al. (1992) Eur. J. Immunol. 22: 447-455: Latza et al. (1995) Am. J. Pathol. 146: 463-471; Chitambar (1991) Blood 78: 2444-2450; Landmann et al. (1992) J. Leukoc. Biol. 52: 323-330; Huizinga et al. (1988) Nature 333: 667-669; And Alderson et al. (1992) J. Immunol. 149: 1252-1257.
In vitro studies with various types of cells have shown that there are two mechanisms involved in the production of soluble receptors and cell surface antigens. One alternatively spliced mRNA lacking transmembrane and cytoplasmic regions leading to the production of soluble IL-4R, IL-5R, IL-7R, IL-9R, GCSF-R, and GM-CSF-R. Entails translation from. Rose-John and Heinrich (1994); And Colotta et al. (1993). Another mechanism involves proteolytic cleavage of the original membrane receptor and antigen, known as "shedding." Proteolysis appears to be involved in the production of soluble LNGF-R, TNF-R, CD27, CD30, IL-1R, IL-6R, TGFβ-R, PDGF-R and CD14 (see above).
Matrix metalloproteinases (MMP) include intracellular collagenase (MMP-1), 72 kDa and 92 kDa gelatinases (MMP-2 and MMP-9), stromelysin 1,2 and 3, Neutrofil Collagenana First, metalloelase, matrylysine, and gelatinase A. These enzymes are secreted by cells in tissues and by invading inflammatory cells. Collectively, they are able to degrade most proteins in the extracellular matrix (ECM).
MMPs exhibit different substrate specificities but still have some properties in common. They are all zinc-containing enzymes that require calcium for their activity. They are secreted as zymogens and are activated in situ by release of inhibitory N-terminal pro-pieces, usually containing a single cysteine residue. Attached pro-pieces are thought to coordinate with zinc at the active site of the proteinase and thereby inhibit proteolytic activity. Activation may be accompanied by additional proteolytic cleavage, which may result in low molecular weight activators. All members of the MMP family have a short conserved region consisting of two Zn-coordinating histidine residues and a HEXGH motif that provides glutamic acid residues that are thought to be part of the catalytic site. Almost without exception, MMPs also contain a hemopexin / Vitronectin domain. The function of the hemopexin domain is unknown. For review, see Ray and Stetter-Stevenson (1994) Eur. Respir. See J. 7: 2062-2072.
Various studies have indicated that MMPs are involved in tumor invasion and metastasis. Many methods have been used to estimate the presence of MMP in human tumor tissue and serum from cancer patients. A positive correlation was found between MMP expression and tumor invasion and metastasis in vivo as well as in animal models. Matrisian et al. (1991) Am. J. Med. Sci. 302: 157-162; Sato et al. (1992) Oncogene 7: 77-83; Lyons et al. (1991) Biochemistry 30: 1449-1456; Levy et al. (1991) Cancer Res. 51: 439-444; Bonfil et al. (1989) J. Natl. Cancer Inst. 81: 587-594; Sreenath et al. (1992) Cancer Res, 52: 4942-4947; And Powell et al. (1993) Cancer Res. 53: 415-422. MMPs have been associated with malignant phenotypes in a wide variety of human tissues including lung, prostate, stomach, colon, breast, ovary and thyroid gland, and also squamous cell carcinoma of the head and neck. Matrisian et al. (1991); Sato et al. (1992); Levy et al. (1991); And Lyons et al. (1991). To date, the proposed role of MMPs in cancer has been limited to tissue remodeling in invasion and metastasis.
MMPs are inhibited by members of a family of tissue inhibitors of metalloproteinases (eg TIMPs, TIMP-1, TIMP-2 and TIMP-3) that bind at the active site and block access to the substrate. Matrix remodeling occurs during several normal pathological processes, depending on the critical balance between activated MMPs and inhibiting TIMPs. For a review of MMPs and their inhibitors, Alexander and Werb (1991), In: Cell Biology of Extracellular Matrix, ed Hay, Plenum Press, New York, pp. 205-302; Murphy et al. (1991) Br. J. Rheumatol. 30: 25-31; Woessner (1991) FASEB J. 5: 2145-2154; Matrisian (1992) Bioessays 14: 455-463; Birkedal-Hansen et al. (1993) Crit. Rev. Oral Biol. and Med. 4: 197-250; And Denhardt et al. (1993) J. Pharmacol. Ther. See 59: 329-341.
Recent studies suggest that metalloproteases are involved in the cleavage of both TNF-Rs, LNGF-R, IL-6R, pro-TNF-I, VCAM-1 and CD30 and are thus responsible for the production of soluble forms. Crowe et al. (1995) J. Exp. Med. 181: 1205-1210; Mullberg et al. (1995) J. Immunol. 155: 5198-5205; Bjornberg et al. (1995) Scand. J. Immunol. 42: 418-424; DiStefano et al. (1993) J. Neurosci. 13: 2405-2414: Mohler et al. (1994) Nature 370: 218-220: Gearing et al. (1994) Nature 370: 555-557; McGeehan et al. (1994) Nature 370: 558-561: Leca et al. (1995) J. Immunol. 154: 1069-1077; And Hansen et al. (1995) Int. J. Cancer (1995) 63: 750-756. Interestingly, MMP is proposed to be responsible for cleavage of pro-TNF-I. Gearing et al. (1994): and Gearing et al. (1995) J. Leukoc. Biol. 57: 774-777. In addition, the levels of serum matrix metalloproteinases 1 and 3 in patients with rheumatoid arthritis were reduced after anti-TNF antibody therapy. Brennan et al. (1997) Br. J. Rheumatology 36: 643-50. Anti-TNF antibodies have also been used to inhibit fever, inflammation, and acute phase reactions in childhood chronic arthritis and rheumatoid arthritis cases and to reverse endotoxin shock in rats. Elliott et al. (1997) Br. J. Rheumatology 36: 589-93; Maini et al. (1997) Apmis 105: 257-63; And Boillot et al. (1997) Crit. Care Medicine 25: 504-11. One MMP inhibitor, GM-6001, prevents the release of TNF both in vitro and in vivo. Solorzano et al. (1997) Shock 7: 427-31.
Numerous MMP inhibitors have been described and their use also includes angiogenesis, wound healing, gum disease, skin disease, keratoconus, inflammatory condition, rheumatoid arthritis, cancer, corneal and skin ulcers, cardiovascular disease, central nervous system disorders, and It has been proposed to treat various pathological signs, including diabetes. US Patent Nos. 5,268,384 and 5,270,326; PCT publications WO 94/22309, WO 95/09913, WO 90/11287, WO 90/14363; EP Patent 211 077, 623 676; And Naito et al. (1994) Int. J. Cancer 58: 730-735; Watson et al. (1995) Cancer Res. 55: 3629-3633; Davies et al. (1993) Cancer Res. 53: 2087-2091; Brown (1995) Advan. Enzyme Regul. 35: 293-301; Sledge et al. (1995) J. Natl. Cancer Inst. 87: 1546-1550; Conway et al (1995) J. Exp. Med. 182: 449-457; And Docherty et al. (1992) TibTech 10: 220-207. However, the ability to treat arthritis by inhibiting matrix metalloproteases has been problematic. Vincenti et al. (1994) Arth. & Rheum. 37: 1115-1126.
Soluble p 55 and p 75 TNF-R do not appear to originate from the processed mRNA only because full-length receptor mRNA was detected in human cells in vitro. Gatanaga et al. (1991). Carboxy terminal sequencing of human soluble p 55 TNF-R indicates that a cleavage site may exist between Asn 172 and Val 173. Gullberg et al. (1992) Eur. J. Cell. Biol. 58: 307-312. This evidence is supported by the finding that human TNF-R with mutations in Asn 172 and Val 173 were not released as effectively as native TNF-R on COS-1 cells transduced with cDNA of human TNF-R. Gullerg et al. (1992). The cytoplasmic portion of TNF-R does not appear to play an important role in releasing soluble receptor forms from transduced COS-1 cells. COS-1 cells release sTNF-R even when transduced with cDNA of human p 55 TNF-R, which expresses only the extracellular domain but does not express the cytoplasmic domain (see above). sTNF-R shedding is not affected by dexamethasone, sodium thiomalate gold or prostaglandin E2. Seitz et al. (1997) J. Rheumatology 24: 1417-6. Overall, these data support the concept that human sTNF-R is produced by proteolytic cleavage of membrane TNF-R protein.
It will be useful to purify and characterize proteases that cleave TNF-R and result in the generation of sTNF-R. Purification and characterization of this proteinase will reveal the role of sTNF-R in host-tumor interactions and in the treatment of pathological conditions mediated or exacerbated by TNF. Although claimed for TRRE (EP 657 536), analysis of the claimed protein sequences provided by BLAST Protein Sequence Homology Search indicates that they fit into TNF-R. This is due to the use of TNF-R affinity columns during protein purification. Thus, the nature of the protein and its DNA and AA sequences are not yet known.
Despite numerous advances in medical research, cancer is the second leading cause of death in the United States. In industrialized countries, approximately one in five people will die of cancer. Conventional methods of clinical protection such as surgical resection, radiotherapy and chemotherapy have a significant failure rate, especially for solid cancers. Failure occurs either because the initial tumor is unresponsive or because of relapse and / or metastasis due to regrowth at the original site. In cancers such as breast cancer, where mortality has been reduced, successful interventions rely on early detection of cancer cells. The etiology, diagnosis and elimination of cancer remain a central focus of medical research and development.
Neoplasia, resulting in benign tumors, can usually be completely healed by surgical removal of the mass. When a tumor becomes malignant, manifested by invasion of surrounding tissues, it becomes much more difficult to eradicate. Once the malignant tumor has spread, it is much less likely to be eradicated.
The three main cancers by morbidity and mortality are colon cancer, breast cancer and lung cancer. New surgical procedures provide increased survival for colon cancer. Improved screening methods increase the detection of breast cancer and allow for less aggressive therapies initially. Lung cancer remains largely refractory to treatment.
Except for basic cell carcinoma, there are over one million new cancer patients every year in the United States alone, and cancer causes more than half a million deaths each year in the United States. In the world, the five most common cancers are lung cancer, stomach cancer, breast cancer, colon / rectal cancer, and cervical cancer, with more than 6 million new patients each year. About half of the cancers die from cancer.
Melanoma is one of the diseases of people in urgent need of new treatment modalities. It is a particularly aggressive form of skin cancer and is occurring at an increased frequency in individuals with regular, unprotected sun exposure. In the early stages of disease, melanoma is characterized by proliferation at the skin-epithelial junction, which soon invades adjacent tissues and spreads widely. Once metastasized, eradication is often impossible and eventually fatal. Globally, 70,000 patients are diagnosed with melanoma annually, causing 25,000 reported deaths each year. The American Cancer Society says that by 2000, one in 75 Americans will be diagnosed with melanoma.
Neuroblastoma is a highly malignant tumor of early childhood and early childhood. With the exception of Wilm's tumor, it is the most common posterior peritoneal tumor in children. These tumors are initially metastasized and involve widespread lymph nodes, liver, bone, lung and bone marrow. Primary tumors are degradable by resection but have a high recurrence rate.
Small cell lung cancer is the most malignant and rapidly growing form of lung cancer, accounting for 20-25% of new lung cancer patients. Approximately 60,000 patients are diagnosed in the United States each year. Primary tumors are generally responsive to chemotherapy, but with wide spread metastases. The median survival time at diagnosis is approximately 1 year and the 5 year survival rate is 5-10%.
Breast cancer is one of the most common cancers and is the third leading cause of cancer deaths in the United States, with an estimated 182,000 new cases and nearly 50,000 deaths annually. In industrial countries, approximately one in eight women is expected to develop breast cancer. The mortality rate of breast cancer has not changed since 1930. The average annual increase was 0.2%, but declined 0.3% annually in women under age 65. Preliminary data suggest that breast cancer mortality rates are beginning to decrease, perhaps as a result of increased in situ diagnosis of local and carcinoma. See, eg, Marchant (1994) Contemporary Management of Breast Discase II: Breast Cancer In: Obstetrics and Gynecology Clinics of North America 21: 555-560; And Colditz (1993) Cancer Suppl. See 71: 1480-1489.
Non-Hodgkin's B-cell lymphoma is a cancer of the immune system that is expected to plague approximately 225,000 patients in the United States in 1996. These cancers vary in prognosis and treatment and are generally classified into one of three classes. The lowest grade median survival time is 6.6 years and higher grade cancers have a much lower life expectancy. Ultimately all non-Hodgkin's B-cell lymphomas are incurable. New diagnoses of non-Hodgkin's lymphomas have increased approximately 7% per year over the past decade and 52,700 new diagnoses have been estimated during 1996. This increase is due, in part, to the increased prevalence of lymphoma in the AIDS patient population.
Despite the difficulties, effective treatment with anticancer drugs (alone or in combination with other treatments) has been devised for some previous high mortality cancers. The most prominent of these are Hodgkin's lymphoma, testicular cancer, choriocarcinoma, and some leukemias and other childhood cancers. For some of the more common cancers, early diagnosis, proper surgery or topical radiotherapy can recover a large proportion of patients.
Current methods of cancer treatment are relatively non-selective. Surgery removes diseased tissue, radiotherapy constricts solid tumors, and chemotherapy quickly kills dividing cells. Chemotherapy is particularly serious, causing numerous side effects and in some cases making the use of potent drugs impossible. Moreover, cancer often develops resistance to chemotherapy.
Recently, methods of in-situ treatment of cancer, particularly pancreatic cancer, have been shown to be effective. The method involves promoting a mixed lymphocyte response (MLR) between host (cancer patients) peripheral blood lymphocytes and donor allogeneic lymphocytes and administering the MLR directly to the tumor. This method is more fully described, for example, in WO 93/20186 and JP62096426. In the case of large solid tumors, administration of MLR is preceded by resection of the tumor.
Like cancer, weight problems are also associated with TNF. TNF is linked to three factors that contribute to weight control: absorption, consumption and energy storage. Administration of TNF or IL-1 causes, for example, reduced food absorption. Rothwell (1993) Int. J. Obesity 17-S98-S101; Arbos et al. (1992) Mol. Cell. Biochem. 112: 53-59; Fargeas et al. (1993) Gastroenterology 104: 377-383; Plata-Salaman et al. (1994) Am. J. Physiol. 266: R1711-1715; Schwartz et al. (1995) Am. J. Physiol. 269: R949-957; And Oliff et al. (1987) Cell 50: 555-563. Interestingly, TNF plays a central role in the extremes of weight problems. The abnormality in its activity may lead to obesity, and a change in its production leads to cachexia, the opposite effect. Argiles et al. (1997) FASEB J. 11: 743-751.
Cachexia is a pathological weight loss commonly associated with anorexia, weakness, anemia, weakness and body fat storage and skeletal muscle protein loss. This condition is accompanied by burns, trauma, infections and neoplastic disease. Lawson et al. (1982) Annu. Rev. Nutr. 2: 277-301; Argiles et al. (1988) Mol. Cell. Biochem. 81: 3-17; And Ogiwara et al. (1994) J. Surg. Oncol. 57: 129-133. TNF levels are elevated in many patients with cachexia. Scuderi et al. (1986) Lancet 2: 1364-65; Grau et al. (1987) Science 237: 1210-1212; and Waage et al. (1986) Scand. J. Immunol. 24: 739-743. TNF inhibits collagen alpha I gene expression and inhibits wound healing in cachexia rat animal models. Buck et al. (1996) Am. J. Pathol. 149: 195-204. In sepsis (invasion of bacteria into the bloodstream), increased endotoxin levels raise TNF levels causing cachexia. Beutler et al. (1985) Science 229: 869-871; Tracey et al. (1987) Nature 330: 662-664; And Michie et al. (1988) New Engl. J. Med. 318: 1481-1486. In cachexia, loss of white adipose tissue is due to reduced activity of lipoprotein lipase (LPL). TNF lowers the activity of this enzyme. Price et al. (1986) Arch. Biochem. Biophys. 251: 738-746; Cornelius et al. (1988) Biochem. J. 249: 765-769; Fried et al. (1989) J. Liped. Res. 30: 1917-1923; Semb et al. (1987) J. Biol. Chem. 262: 8390-8394; And Evans et al. (1988) Biochem. J. 256: 1055-1058. Adipose tissue loss is also associated with increased lipase activity and inhibition of glucose transport. TNF is also linked to both of these changes. Kawakami et al. (1987) J. Biochem. 331-338; Feingold et al. (1992) Endocrinology 130: 10-16; And Hauner et al. (1995) Diabetologia 38: 764-771. TNF mediates triglyceride excess associated with cachexia. Dessi et al. (1995) Br. J. Cancer 72: 1138-43. TNF is also involved in protein consumption, skeletal muscle loss and nitrogen loss associated with cachexia. Costelli et al. (1993) J. Clin. Invest. 92: 2783-2789; Folres et al. (1989) J. Clin. Invest. 83: 1614-1622; Goodman (1991) Am. J. Physiol. 260: E 727-730; Zamir et al. (1992) Arch. Surg. 127: 170-174; Llovcra et al. (1993) J. Natl. Cancer Inst. USA 85: 1334-1339; And Garcia-Martinez et al. (1993) FEBS Lett. 323: 211-214.
TNF plays additional related roles. It is accompanied by heat generation, especially non-rate heat generation, in brown adipose tissue (BAT) with high levels in cachexia. Nicholls (1983) Biosci. Rep. 3: 431-441; Rothwell (1993) Int. J. Obesity 17: S98-S101; Bianchi et al. (1989) Horm. Metab. Res. 21:11; And Oudart et al. (1995) Can. J. Physiol. Pharmacol. 73: 1625-1631. TNF has also been associated with non-insulin dependent (type II) diabetes. Hotamisligil et al. (1995) J. Clin. Invest. 95: 2409-2415; Arner (1996) Diabetes Metab. 13: S85-S86; Spiegelman et al. (1993) Cell 73: 625-627; Saghizadeh et al. (1996) J. Clin. Invest. 97: 1111-16; And Hofmann et al. (1994) Endocrinology 134: 264-270. These data help to explain how TNF mediates the opposite effects of obesity and cachexia. TNF has a functional similarity to leptin, which has been proposed to be an "adipostat". Zhang et al. (1994) Nature 372: 425-432; Phillips et al. (1996) Nature Genet. 13: 18-19; And Madej et al. (1995) FEBS Lett. 373: 13-18. Like leptin, for example, TNF is expressed and secreted by adipocytes and can migrate to the brain. TNF administration also results in an increase in circulating leptin concentrations. Grunfeld et al. (1996) J. Clin. Invest. 97: 2152-57. It is possible to coordinate the involvement of TNF in obesity and cachexia. TNF may be thought to be one of many signals from adipose tissue involved in a feedback mechanism that informs the hypothalamus center for the state of adipocyte energy storage. It may possibly stimulate thrombosis by neutralizing excess energy absorption and directly or by increasing sympathetic activity. TNF released by adipose tissue also stimulates lipolysis and decreases LPL activity, decreases the expression of glucose transporter GLUT4, inhibits lipoogenesis of adipocytes and thus maintains fat tissue mass (but does not increase fat adhesion). Not). However, in cachexia, the situation is different. High production of TNF by activated macrophages (as a result of tumors or infections) also contributes to anorexia, increased heat generation, and adipose tissue lysis. However, it represents a pathological condition with excess molecules that tell the brain that adipose tissue needs dissolution. Thus, both situations can be adjusted. That is, there is a pathological overproduction of TNF in cachexia, and the physiological action of TNF is impaired as a signal for controlling food absorption and energy consumption in obesity. Argiles et al. (1997) FASEB J. 11: 743-751.
Summary of the Invention
The present invention includes compositions of substantially purified proteins having tumor necrosis factor (TNFR) releasing enzymatic activity, ie TRRE. The protein can be purified by any method known in the art, perhaps in the same manner as described in the Examples below. In one embodiment, TRRE in its native form has an apparent molecular weight of about 120 kDa on sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE). In another embodiment of the invention, the TRRE has the following internal amino acid sequence: D-L-N-L-G-A-Q-A-T-I-T-N-L-P (SEQ ID NO: 1); G-L-D-E-T-Q-N-L-I-T-V-P-Y (SEQ ID NO: 2); S-E-R-W-P-Q-M-A-N-K-V-S-R (SEQ ID NO: 3); I-V-V-T-K (SEQ ID NO: 4); E-F-P-H / S-P-V-D-A-A-T-R (SEQ ID NO: 5); A-L-F-E-L-I-Y-E-L-L-L / E-A-Y-I-I / N-V-L (SEQ ID NO: 6); L-D-Y-Q-E / T-S-Y-S-A-A-V-A-R (SEQ ID NO: 7); L-A-L-Q / I-E-S-P-S / P (SEQ ID NO: 8); L-F-L-K-N-T-G-L-A-R (SEQ ID NO: 9); M-A-L-Q-K-G-D-R (SEQ ID NO: 10); K-L-L-E-L-N-V-V-A (SEQ ID NO: 11); V / I-T-D-M-V-V-G-I-X-G (SEQ ID NO: 12) where X is an unidentified amino acid residue; L-V-D-Y-D-X-L-F-Q-N-L (SEQ ID NO: 13); And / or K-E-A-L-I-A-K-I-R (SEQ ID NO: 14). Alternatively, in another embodiment of the present invention, the native form of TRRE has an apparent molecular weight of about 60 kDa in SDS-PAGE. In another embodiment, the TRRE has the following internal amino acid sequence: D-L-N-L-G-A-Q-A-T-I / L-T-N-L-P (SEQ ID NO: 15); L-A-E-D-Y-L-S-G / L-W-L-E / G-R (SEQ ID NO: 16); And / or L / K-V / L-D / E-Y-D / E-X-L / F-F-Q-N-L (SEQ ID NO: 17). Fragments of TRRE containing TRRE activity are also included in the present invention.
The present invention also includes methods of treating diseases associated with altered levels or activity of tumor necrosis factor. The method comprises administering an amount of TRRE sufficient to indirectly mitigate or control the local level of tumor necrosis factor.
The present invention likewise includes methods of treating diseases associated with elevated levels of soluble TNF-R. The method comprises administering an amount of inhibitor of TRRE that is effective to reduce the level of soluble TNF-R.
The present invention also provides a method for diagnosing a disease associated with a high level of TRRE, comprising obtaining a biological sample from a patient, measuring the activity of TRRE in the sample and comparing the measured activity to the TRRE activity of a control biological sample. It includes. Excess TRRE activity compared to the control is an indication of the presence of a disease state associated with high levels of TRRE.
The present invention also includes methods of treating diseases associated with reduced levels of tumor necrosis factor. The method comprises administering an amount of inhibitor of TRRE sufficient to modulate the level of TNF-TNF receptor on the cell surface.
The present invention also includes methods for measuring TRRE activity. The method compares TNF-R release in TNF-R expressing cells (TNF-R ⁺ ) incubated with TRRE to TNF-R release by TNF-R ⁺ cells not incubated with TRRE and also a significant amount of TNF -R (TNF-R ^-) by cells which do not express the a step of comparison with the TNF-R release. The amount of emitted by the quantity and TNF-R ^_ cells emitted by the TNF-R ⁺ cells without TRRE in the amount of the released by the TNF-R ⁺ cells incubated with TRRE TNF-R TNF-R TNF-R Subtracting gives the amount of TRRE in the sample. Preferably the TNF-R ⁺ cells are recombinant TNF-R ^_ cells transformed to recombinantly express TNF-R.
The present invention also includes methods for screening agents that modulate the activity of TRRE. TRRE activity is measured in the presence (test) or absence (control) of a particular drug or drug. If the activity of the test sample is excess or less than that of the control, the drug or drug increases or decreases TRRE activity, respectively.
The present invention relates to the purification and characterization of tumor necrosis factor (TNF) receptor (TNF-R) release enzyme (TRRE), compositions derived from enzymes and methods of use thereof. Adjusting the TRRE level indirectly adjusts the effective level of the TNF. The present invention also relates to or exacerbates the altered levels or activity of TNF, such as inflammatory conditions, including conditions associated with reduced levels or activity of TNF, such as autoimmune disease, hepatitis, sepsis shock, obesity, cachexia, and cancer. It relates to a method of treatment of pathological conditions.
1 is a schematic of plasmid pCDTR2 expressing p75 TNF-R. pCMV represents cytomegalovirus and BGHpA represents a phytohormonal polyadenylation signal.
2 is a graph depicting the measurement results of p75 TNF-R in COS-1 cells (C75R) transfected by the method described herein. The result obtained by C75R cells (●) is compared with the result obtained by parental COS-1 cells (■). Receptor numbers were calculated from Scatchard plots (insertions).
3 is a bar graph depicting the results of TRRE on TNF binding to C75R.
4 depicts the results of Western blot analysis of soluble receptors released from C75R cells by TRRE.
5 is a series of graphs depicting the time course of TNF-R shedding induced by TRRE. 5A depicts a short course (5-30 minutes) and FIG. 5B depicts a long passage (30-90 minutes).
6 is a graph depicting the time course of TRRE induction from PMA-stimulated cells. The kinetics of TRRE activity and sTNF-R were performed for an incubation time of 3-24 hours including the initial 30 minute PMA-stimulation time.
7 is a graph depicting the effect of a series of dilutions of TRRE medium on the production of sTNF-R.
8 is a schematic depicting the effect of continued PMA stimulation of THP-1 cells on TRRE production.
9 depicts the induction of TRRE from THP-1 cells treated with various cytokines and hormones.
10A is a histogram depicting TRRE activity in PMA-stimulated THP-1 cells and controls. FIG. 10B is a photograph of gelatin zymography of the samples listed in FIG. 10A. 10C is a histogram depicting TRRE activity of gelatin zymography in partially purified TRRE samples. FIG. 10D is a photograph of gelatin zymography corresponding to the sample in FIG. 10C.
FIG. 11 is a graph depicting TRRE activity of fractions obtained using Sephadex G-150 column. Each fraction (1 mL) was analyzed for TRRE activity (•) and soluble p75 TNF-R (■) and absorbance at 280 nm (▲) was measured. Peak elution of standard, beta-amylase (200 kDa) and bovine serum albumin (66 kDa) is shown.
12A depicts the results obtained from the affinity column of soluble p75 TNF-R. The total amount of TRRE recovered from the affinity column is adjusted to 100%. 12B depicts the continued treatment of the same TRRE sample for C75R cells. The TRRE activity of the first treatment on C75R is adjusted to 100%.
13 depicts the results obtained from cleavage of both p55 and p75 TNF-R on THP-1 cells by TRRE.
14 is a graph depicting the effect of TRRE on various cell surface antigens.
15 is a graph depicting the results of modified ex vivo TNF lysis assay by TRRE treatment on L929 cells.
FIG. 16 is a graph depicting the DEAE-Sephadex profile of Sample A obtained in Example 5. FIG.
17 is a photograph of the native PAGE profile of Sample B obtained in Example 5. FIG. FIG. 17A depicts the TRRE activity of each sliced piece (fraction) and FIG. 17B depicts the silver-stained native PAGE corresponding to FIG. 17A. In FIG. 17B, the left side is the top of the gel.
18 is a photograph of SDS-PAGE of the highest TRRE eluate of native PAGE of Sample A obtained in Example 5. FIG.
19 is a graph depicting the effect of TRRE on preventing mortality in mice treated with lipopolysaccharide (LPS) causing septic peritonitis.
20 is a bar graph demonstrating TRRE activity in human lung tumor tissue (black bars) or adjacent non-tumor tissues (bar rods).
TNF is the main pro-inflammatory and immunoregulatory cytokine produced during the immune response. TNF also appears to be required to modulate the expression of IL-2R to lead to enhanced T cell responses mediated by IL-2 and to generate proliferative responses in mixed lymphocyte cultures. Further research suggests that CD8 ⁺ , CTL and lymphocyte-activated killer cells are optimally induced with TNF in combination with IL-2, suggesting the importance of this cytokine in regulating cytotoxic effector function. As discussed in detail above, TNF modulates its activity by binding to TNF-R. Soluble TNF-R inhibits TNF activity in two ways. That is, they reduce the useful binding site in the cell and bind to soluble TNF to reduce local concentrations. The present invention includes compositions and methods for modulating levels of soluble TNF-R by reducing cleavage of TNF-R from the cell surface and thus indirectly modulating the effects of TNF.
In the present invention, a novel analytical system has been devised to detect and quantify TRRE resulting in the generation of sTNF-R. Proteolytic activity derived from PMA-stimulated THP-1 cells (human tumor monocyte cell line) in the medium was defined as TNF-R release enzyme (TRRE). Based on this analysis system, TRRE was characterized and refined. The invention also includes TRRE analysis, discussed in more detail below.
The present invention includes a composition of a substantially purified protein having a tumor necrosis factor receptor (TNFR) releasing enzyme activity called TRRE. The protein can be purified as described in the Examples below and in addition to having the enzymatic activity described, the native enzyme has an apparent molecular weight of about 120 kDa on SDS-PAGE. In some embodiments of the invention, the TRRE has the following internal sequences: D-L-N-L-G-A-Q-A-T-I-T-N-L-P (SEQ ID NO: 1); G-L-D-E-T-Q-N-L-I-T-V-P-Y (SEQ ID NO: 2); S-E-R-W-P-Q-M-A-N-K-V-S-R (SEQ ID NO: 3); I-V-V-T-K (SEQ ID NO: 4); E-F-P-H / S-P-V-D-A-A-T-R (SEQ ID NO: 5); A-L-F-E-L-I-Y-E-L-L-L / E-A-Y-I-I / N-V-L (SEQ ID NO: 6); L-D-Y-Q-E / T-S-Y-S-A-A-V-A-R (SEQ ID NO: 7); L-A-L-Q / I-E-S-P-S / P (SEQ ID NO: 8); L-F-L-K-N-T-G-L-A-R (SEQ ID NO: 9); M-A-L-Q-K-G-D-R (SEQ ID NO: 10); K-L-L-E-L-N-V-V-A (SEQ ID NO: 11); V / I-T-D-M-V-V-G-I-X-G (SEQ ID NO: 12), wherein X is an unidentified amino acid residue; L-V-D-Y-X-L-F-Q-N-L (SEQ ID NO: 13); And K-E-A-L-I-A-K-I-R (SEQ ID NO: 14). Alternatively, the native form of TRRE has an apparent molecular weight of about 60 kDa on SDS-PAGE. In some embodiments of the invention, the TRRE comprises D-L-N-L-G-A-Q-A-T-I / L-T-N-L-P (SEQ ID NO: 15); L-A-E-D-Y-L-S-G / L-W-L-E / G-R (SEQ ID NO: 16); And the internal amino acid sequence of L / K-V / L-D / E-Y-D / E-X-L / F-F-Q-N-L (SEQ ID NO: 17). Where X is an unidentified amino acid residue. The band pattern on SDS-PAGE is somewhat diffuse, indicating that the protein is a glycoprotein. Thus, recombinant proteins (ie, "non-native" proteins) have an apparent molecular weight that depends on the degree of glycosylation.
The enzymatic activity of TRRE is inhibited by metalloprotease inhibitors. Thus, methods of inhibiting the activity of TRRE by addition of metalloprotease inhibitors are also included in the present invention.
The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acid residues of any length. The polymer may be linear or separated. It may consist of modified amino acids or amino acid analogs or may be blocked by chemical moieties other than amino acids. These terms also include amino acid polymers modified naturally or by intervening. For example, any other manipulation or modification, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or labeling or binding to a bioactive component. Unless otherwise stated or implied, the term TRRE includes any polypeptide monomer or polymer having TRRE enzymatic specificity, including native TRRE, small and large functionally equivalent polypeptides as described herein.
A "fusion polypeptide" is a polypeptide that comprises regions that occur naturally and at different positions in the sequence. The regions are usually in separate proteins and brought together in the fusion polypeptide, usually in the same protein but in a new arrangement in the fusion polypeptide, or they may be arranged synthetically. For example, as described below, the present invention includes recombinant proteins consisting of antibodies and functional parts of TRRE. Methods of making these fusion proteins are known in the art and are described, for example, in WO 93/07286.
A "functionally equivalent fragment" of a TRRE polypeptide changes from its native sequence by addition, deletion or substitution or combination thereof while preserving at least one functional property of the relevant fragment used. Functionally equivalent fragments of TRRE polypeptides typically have the ability to bind membrane-bound TNF-R and enzymatically cleave TNF-R to provide soluble TNF-R. Amino acid substitutions, if present, are preferably conservative substitutions that do not deleteriously affect the folding or functional properties of the peptide. Groups of functionally related amino acids for which conservative substitutions can be made are glycine / alanine, valine / isoleucine / leucine, asparagine / glutamine, aspartic acid / glutamic acid, serine / threonine / methionine, lysine / arginine and phenylalanine / tyrosine / tryptophan. Polypeptides of the invention may be in glycosylated or aglycosylated form and may be post-translational (eg, removal of signal peptides, transmembrane or cytoplasmic regions, acetylation, and phosphorylation) or modified synthetically ( For example, by a labeling machine).
The invention also includes compositions of TRRE and physiologically acceptable buffers. Suitable physiologically acceptable buffers include, but are not limited to, saline or phosphate buffered saline (PBS). When attempting to administer TRRE to an individual, it should preferably be at least 80% pure, more preferably at least 90% pure and even more preferably at least 95% pure and free of pyrogen and other contaminants. In the text, percent purity is calculated as weight percent of the total protein content of the formulation and does not include components that are intentionally added to the composition after the TRRE is purified.
The invention also encompasses antibodies (or antigen binding fragments thereof) specific for the TRRE protein. The composition contains a therapeutically effective amount of a substantially purified antibody binding fragment specific for TRRE. Preferably, the antibody neutralizes TRRE INF-R releasing activity. Methods of antibody production and isolation are well known in the art. See, eg, Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York. Antibodies can be isolated by any technique suitable for immunoglobulins of this isotype. Purification methods include salt precipitation (eg, with ammonium sulfate), ion exchange chromatography (eg, in a cation or anion exchange column run at neutral pH eluted with a step gradient of increasing ionic strength), gel filtration chromatography Graphigraphy (including gelfiltration HPLC), and chromatography on affinity resins such as protein A, protein G, hydroxyapatite, and anti-immunoglobulins. Anti-TRRE antibodies can also be purified on affinity columns comprising TRRE. Preferably, the anti-TRRE antibody is purified using Protein-A-CL-Sepharose ^™ 4B chromatography followed by chromatography on a DEAE-Sepharose ^™ 4B ion exchange column.
The term “antigen-binding fragment” includes any peptide that binds to TRRE in a particular way. These derivatives include H and L chains separated from immunoglobulin fragments such as Fab, F (ab ') ₂ , Fab', scfv (both in monomer or polymer form). Antigen binding fragments retain the specificity of intact immunoglobulins, but the avidity and / or affinity can be altered.
Antigen-binding fragments (also referred to herein as "derivatives") are typically generated by genetic engineering, but can alternatively be obtained by other methods and combinations of methods. This classification includes, but is not limited to, genetically engineered peptide fragments and fusion peptides. Preferred compounds include polypeptide fragments of CDRs, antibody fusion proteins consisting of cytokine effector components, antibody fusion proteins consisting of adjuvants or drugs, and single chain V region proteins.
Scfv can be produced recombinantly or synthetically. For the synthetic production of scfv, an automated synthesizer can be used. For recombinant production of scfv, suitable plasmids containing polypeptides encoding scfv can be introduced into and expressed in eukaryotic cells such as yeast, plants, insects or mammalian cells or in suitable host cells of prokaryotes such as E. coli. The purified protein can be separated using standard protein purification techniques.
A particularly useful system for the production of scfv is plasmid pET-22b (+) (Novagen, Madison, WI) in E. coli. pET-22b (+) contains a nickel ion binding domain consisting of six consecutive histidine residues which allow the expressed protein to be purified on a suitable affinity resin. Another example of a suitable vector is pcDNA3 (Invitrogen, San Diego, Calif.) Described above.
The invention also includes hybrid antibodies in which a pair of H and L chains are obtained from a first antibody, while other pairs of H and L chains are obtained from another second antibody. For the purposes of the present invention, the pair of L and H chains are from anti-TRRE. In one embodiment, each L-H chain pair binds to other epitopes of TRRE. Such hybrids can also be formed using humanized H or L chains. Also included in the present invention are peptides in which various immunoglobulin domains are placed in an order other than what occurs in nature. In addition, the antigen binding fragments of the present invention can be used as diagnostic and imaging reagents.
The invention also includes polynucleotides encoding antibodies (or fragments thereof) capable of binding to TRRE polypeptides (or fragments thereof). Polynucleotides may be natural or recombinant and may be included in a vector or plasmid and operably linked to a promoter.
The invention also includes methods of treating diseases associated with altered levels or activity of TNF by administering an amount of TRRE sufficient to indirectly reduce local levels of TNF. Appropriate signs for treatment include autoimmune diseases such as cancer, diseases such as obesity and cachexia, diabetes, childhood onset rheumatoid arthritis, systemic lupus erythematosus, and other inflammatory conditions, psoriasis, endotoxin shock, rheumatoid arthritis, trauma, And multiple sclerosis. Infections associated with microbial or parasitic infections in which TNF plays an important role include, but are not limited to, septic shock and malaria. In addition, TRRE can be used to treat indications previously associated with variant MMP expression. As noted above, these include but are not limited to angiogenesis, wound healing, gum disease, skin disease, keratoconus, inflammatory condition, rheumatoid arthritis, cancer, corneal and skin ulcers, cardiovascular disease, central nervous system disorders, and diabetes It is not limited to. Also included are tissue destruction components in which TNF plays an important role such as Crohn's disease and inflammatory bowel disease and immuno-inflammatory diseases with immunological basis. Other inflammatory conditions, such as trauma shock, are also included.
Dosage methods include anything known in the art. Preferably, it is administered directly to the site of inflammation in the case of rheumatoid arthritis, and parenteral, subcutaneous, intramuscular, intestinal, intraluminal, intrathecal, and intravenous in case of systemic disease. Administration may also be systemic to treat local disease or local to treat systemic disease. Methods of administration are discussed in more detail below. For example, topical administration can be achieved by topical injection during surgery, by direct injection into the site, by catheter, or by implantation, the implant comprising a membrane or fiber, such as a plastic membrane. Is a porous, nonporous or gelatinous material. Suitable such membranes are Gliadel provided by Guilford Sciences. to be.
Treatment of external diseases such as psoriasis is by topical treatment. Accordingly, the present invention further comprises a composition of an effective amount of TRRE and a topically pharmaceutically or cosmetically acceptable carrier.
As used herein, a "topical pharmaceutically acceptable carrier" is any substantially nontoxic carrier conventionally useful for topical administration of a drug that remains stable and bioavailable when TRRE is applied directly to the skin or mucosal surface. For example, TRRE can be dissolved in a liquid and dispersed or emulsified in a medium in a conventional manner to form a liquid formulation or mixed with a semisolid (gel) or solid carrier to form a paste, powder, ointment, cream, lotion, or the like. have.
Suitable topically pharmaceutically acceptable carriers include organic and inorganic waxes, such as water, petroleum jelly (Vaseline ^™ ), waseline, mineral oil, vegetable oil, animal oil, microcrystalline paraffin and ozoselite wax, xanthan, gelatin, cellulose, Natural polymers such as collagen, starch or gum arabic, synthetic polymers as discussed below, alcohols, polyols and the like. The carrier may be a water miscible carrier composition that is substantially miscible with water. Such water-miscible topical pharmaceutically acceptable carrier compositions may include those made from one or more of the appropriate ingredients set forth above and may also contain liposomes, microsponges, microspheres or microcapsules, hand-made ointments, water-in-oil or oil-in-water emulsions. Sustained or delayed release carriers, including water-containing, water-dispersible or water-soluble compositions such as gels, and the like.
In one embodiment of the invention, the topically pharmaceutically acceptable carrier consists of a sustained release or delayed release carrier. The carrier may be any substance that is easy to handle TRRE for more effective administration resulting in one or more less frequent and / or reduced TRRE dosages, and which may have a prolonged or delayed effect on the skin condition. The carrier may release TRRE by diffusion or by release, depending on the extent of TRRE to the carrier when exposed to any oily, fatty, waxy, or wet environment in the area to be treated to obtain release of TRRE. Unlimited examples of such carriers include liposomes, microsponges, microspheres, or microcapsules such as natural and synthetic polymers. Examples of suitable carriers for sustained or delayed release in moist environments include gelatin, gum arabic, xanthan polymers; Depending on the degree of charge, it contains lignin polymers and the like, and is based on an oily, fatty or waxy environment, thermoplastic resins such as polyvinyl halides, polyvinyl esters, polyvinylidene halides and halogenated polyolefins, brasiliensis, polydienes and Elastomers such as halogenated natural and synthetic rubbers, and thermoplastic or flexible thermosetting resins or elastomers, including flexible thermosetting resins such as polyurethanes, epoxy resins, and the like. Preferably, the sustained or delayed release carrier is a liposome, microsponge, microspheres or gel.
The composition used in the method of treating the skin condition of the present invention is applied directly to the area to be treated. Although not required, the topical composition maintains TRRE at the desired location for about 24 to 48 hours.
If desired, one or more additional ingredients conventionally found in topical or cosmetic compositions may be included with the carrier, such as vitamins such as moisturizers, wetting agents, communicators, buffers, pigments, preservatives, vitamins A, C and E, Emulsifiers, dispersants, wetting agents, pharmaceutics, gelling agents, stabilizers, propellants, antimicrobial agents, sunscreen agents, enzymes and the like. One skilled in the art of topical pharmaceuticals can readily select suitable additional ingredients and amounts thereof. Suitable unlimited examples of additional ingredients include superoxide dismutase, stearyl alcohol, isopropyl myristate, sorbitan monooleate, polyoxyethylene stearate, propylene glycol, water, alkali or alkaline earth metal lauryl sulfate, methyl paraben , Octyldimethyl-p-aminobenzoic acid (Padimate O), uric acid, reticulin, polymucosaccharides, hyaluronic acid, aloe vera, lecithin, polyoxyethylene sorbitan monooleate, vitamin A or C, tocopherol (vitamin E), Alphahydroxy or alphaketo acids, such as pyruvic acid, lactic acid or glycolic acid, or any of the topical ingredients disclosed in US Pat. Nos. 4,340,586, 4,695,590, 4,959,353, or 5,130,298 and 5,140,043.
Since the skin condition to be treated is visible, the topical carrier can also be a carrier acceptable for topical cosmetics. As used herein, "a topical cosmetically acceptable carrier" means any substantially non-toxic carrier conventionally useful for topical administration of cosmetics that remains stable and bioavailable when TRRE is applied directly to the skin surface. Suitable cosmetically acceptable carriers are known to those skilled in the art and include liquids, creams, oils, lotions, ointments or conventional cosmetic night creams, foundation creams, suntan lotions, sunscreens, hand lotions, makeup and makeup bases, Solids such as masks and the like, but are not limited thereto. Thus, to a substantial extent, the initial discussion of similar and pharmaceutically acceptable carriers in nature also applies to cosmetically acceptable carriers, unless the carriers used in topical cosmetics and the pharmaceutically acceptable carriers are often not identical. Compositions include perfumes, estrogens, vitamins A, C or E, alphahydroxy or alphaketo acids such as pyruvic acid, lactic acid or glycolic acid, lanolin, Vaseline ^™ petroleum jelly, aloe vera, methyl or propyl parabens, pigments and the like May contain other ingredients customary for.
The effective amount of TRRE in a composition used to treat a skin condition or disease depends on factors such as skin condition, skin age, purity of TRRE used, formulation type and carrier components used, frequency of administration, and overall health of the individual to be treated. can be different. The exact amount for the particular patient used can be determined by one of ordinary skill in the art of pharmacy in view of these factors and the present specification. Preferably the composition is administered up to about 6 doses at least twice daily, or less when sustained or delayed release forms are used.
Compositions for topical, oral and parenteral administration usually contain from about 0.001% to about 10% by weight of TRRE, preferably from about 0.01% to about 2% by weight TRRE, in particular based on the total weight of the composition It contains from about 0.1% to about 1.5% TRRE by weight of the composition.
Topical compositions are administered by applying a coating or layer to the skin or mucosal area for treatment. For practical convenience, the coating material is rubbed onto the site. The coating does not need to rub on the skin and a layer or coating may remain on the skin overnight.
The amount of TRRE administered is sufficient to effectively reduce the level of TNF. Typically, reduced TNF levels result in relief of symptoms. Mitigation represents a reduction in the deleterious effects of cancer on the individual. Administration is typically done locally or every two weeks until the desired measurable variable, such as reduction of disease symptoms, is detected. Dosing can then continue every two weeks or less frequently, if appropriate. Effective amounts are readily determined by those skilled in the art. The dosage range is large enough to produce the desired effect of alleviating the symptoms of the disease without causing undesired side effects such as unwanted cross reactions, anaphylactic reactions, and the like. In general, the dosage will vary depending on the age, condition, sex, and severity of the patient and can be determined by one skilled in the art. The dosage can be adjusted by the individual physician in any complex case.
The present invention also includes methods of treating diseases associated with high levels of soluble TNF-R by administering an amount of inhibitor of TRRE effective to reduce the level of soluble TNF-R. Preferably the disease to be treated is cancer. More preferably, the cancer is astrocytoma, oligodendrosis, supercytopathy, medulloblastoma, primitive neuroectodermal tumor, pancreatic ductal adenocarcinoma, bovine and large cell lung adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, epithelial adenocarcinoma and its metastases, Liver cancer, cholangiocarcinoma, duct and lobular cancer, squamous and adenocarcinoma of the cervix, epithelial cell carcinoma of the uterus and ovary, prostate adenocarcinoma, transitional squamous bladder cancer, B and T-cell lymphoma (lobe and diffuse), plasmacytoma, acute and chronic leukemia , Malignant melanoma, soft tissue sarcoma, and leiomyoma.
TRRE inhibitors can be any known to those of skill in the art and include metalloprotease inhibitors, antibodies that block the effective interaction between TNF-R and TRRE, antisense oligonucleotides specific for genes encoding TRRE, and genes encoding TRRE. Including but not limited to specific ribozymes. Methods of making antibodies are known in the art. Antibodies that block the effective binding of TRRE to TNF-R are easily screened by using the assays described herein.
The dosage range for administration of a TRRE inhibitor is a dosage range large enough to produce the desired effect of alleviating the symptoms of malignant disease without causing adverse side effects such as unwanted cross reactions, anaphylactic reactions, and the like. In general, the dosage will vary depending on the age, condition, sex and severity of the patient and can be determined by one skilled in the art. The dosage can be adjusted by the individual physician in any complex case. For example, when the inhibitor is an antibody, the dosage is about 0.1 mg / kg to about 2000 mg / kg, preferably about 0.1 mg / kg to about 500 mg / kg, in one or more doses per day. It can vary. In general, lower dosages may be used when the antibody is administered in combination with a therapeutic agent.
Therapeutic compositions of TRRE inhibitors may be administered by injection or by gradual perfusion over time. Inhibitors may be administered alone or in combination with effector cells intravenously, intraperitoneally, intramuscularly, subcutaneously, intraluminally, intrathecal or transdermally.
Preferably in the case of cancer treatment, the administration is administered by injection directly into the tumor, for example directly into the tumor. Intralesional administration of various immunotherapeutic forms to cancer patients does not cause the toxicity seen by systemic administration of immunological drugs. Fletcher et al. (1987) Lymphokine Res. 6:45; Rabinowich et al. (1987) Cancer Res. 47: 173; Rosenberg et al. (1989) Science 233: 1318; And Pizz et al (1984) Int. J. Cancer 34: 359. Preferably, intralesional administration is described, for example, in US Pat. The cancer therapy techniques described in 5,376,682, 5,192,537 and 5,643,740.
When the delivery site is the brain, the therapeutic agent must be able to deliver to the brain. Blood flow barriers limit the absorption of many therapeutic agents from the general circulation into the brain and spinal cord. Molecules crossing the bloodstream barrier use two main mechanisms: free diffusion and accelerated transport. Because of the presence of the blood-brain barrier, achieving an advantageous concentration of a given therapeutic agent in the CNS may require the use of a drug delivery strategy. Delivery of the therapeutic agent to the CNS can be accomplished by several methods.
One method relies on neurosurgery. In the case of severely ill patients, surgical intervention is warranted despite the associated risks. For example, the therapeutic agent can be delivered by direct physical introduction into the CNS, such as intraventricular, intralesional, or intrathecal injection. Intraventricular injection can be facilitated by an intraventricular catheter attached to a reservoir, for example an Ommaya reservoir. Methods of introduction may also be provided by rechargeable or biodegradable devices. Another approach is the breakdown of the blood-brain barrier by substances that increase the permeability of the blood-brain barrier. Examples include poor articulating agents such as mannitol, drugs that increase cerebrovascular permeability such as etoposide, or intraarterial injection of vascular active agents such as leukotriene. Neuwlt and Rappoport (1984) Fed. Proc. 43: 214-219: Baba et al. (1991) J. Cereb. Blood Flow Metab. 11: 638-643; And Gennuso et al. (1993) Cancer Invest. 11: 638-643.
It may also be desirable to administer the composition locally to the area in need of treatment, which may be achieved, for example, during surgery, by injection, by catheter, or by implantation. Of porous, nonporous, or gelatinous materials, including membranes such as plastic membranes or fibers. Suitable such membranes are Gliadel provided by Guilford Sciences. to be.
Another method involves pharmacological techniques such as modification or selection of inhibitors to provide analogs that will cross the blood-brain barrier. Examples include increasing the hydrophobicity of the molecule, decreasing the net charge or molecular weight of the molecule, or modifying the molecule to resemble what is normally transported across the blood-brain barrier. Levin (1980) J. Med. Chem. 23: 682-684; Pardridge (1991) in: Peptide Drug Delivery to the Brain; And Kostis et al. (1994) J. Clin. Pharmacol. 34: 989-996.
Encapsulation of inhibitors in hydrophobic environments such as liposomes is also effective for delivering drugs to the CNS. For example, WO 91/04014 describes liposome delivery systems in which drugs are encapsulated in liposomes to which molecules are normally transported across the blood-brain barrier.
Another method of formulating inhibitors to cross the blood-brain barrier is encapsulation in cyclodextrins. Any suitable cyclodextrin that crosses the blood-brain barrier can be used, -Cyclodextrins, K-cyclodextrins and derivatives thereof. In general, U.S. Patent Nos. 5,017,566, 5,002,935 and 4,983,586. Such compositions are also described in US Pat. Glycerol derivatives as described by 5,153,179.
Yet another method uses physiological techniques such as binding of inhibitors to transportable agents to yield new chimeric transportable ICs. For example, the vascular active intestinal peptide analog (VIPa) had only its vasoactive effect after binding of Mab to a specific carrier molecule transferrin receptor that facilitated uptake of VIPa-Mab through the blood-brain barrier. Pardridge (1991) and Bickel et al. (1993) Porc. Natl. Acad. Sci. USA 90: 2618-2622. Several other specific transport systems have been identified and these include, but are not limited to, those that carry insulin, or insulin like growth factors I and II. Other suitable nonspecific carriers include, but are not limited to, pyridinium, fatty acids, inositol, cholesterol, and glucose derivatives. Certain prodrugs have been described so that when entering the central nervous system, the drug is cleaved from the carrier to release the active drug. U.S. Patent No. 5,017,566.
TRRE inhibitors may be administered in association with at least one cytokine that is effective to enhance an immune response against cancer. Suitable cytokines include, but are not limited to, TNF, interleukin 2 (IL-2), interleukin 4 (IL-4), granulocyte macrophage colony stimulating factor (GM-CSF), and granulocyte colony stimulating factor (GCSF). It doesn't work.
TRRE inhibitors may also be administered in connection with at least one chemotherapeutic agent. Suitable chemotherapeutic agents are radioisotopes, vinca alkaloids, adriamycin, bleomycin sulfate, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, duanorubicin hydrochloride, doxorubicin Hydrochloride, etoposide, fluorouracil, romastin, mechlororetamine hydrochloride, melphalan, mercaptopurine, methotrexate, mitomycin, mitotan, pentostatin, fibrobroman, procarbaz hydrochloride, streptozotocin, Taxol, thioguanine, and uracil mustard.
Suitable patients include patients suspected of being at risk of pathological effects of certain neoplasms, in particular cancer, and suitable for treatment with the pharmaceutical compositions of the present invention. Patients with a history of cancer are particularly suitable. Suitable human patients for treatment consist of two groups that can be distinguished by clinical criteria. Patients with “advanced disease” or “high tumor burden” are patients with clinically measurable tumors. Clinically measurable tumors are identified on the basis of tumor mass (e.g., by palpation, CAT scan, or X-ray; positive biochemical or histopathological markers for themselves identify this population). Insufficient). The pharmaceutical compositions embodied in the present invention are administered to these patients to induce anti-tumor responses for the purpose of temporarily relieving their condition. Ideally, a reduction in tumor mass would result, but any clinical improvement would be an advantage. Clinical improvements include a reduced risk or rate of progression or reduction of the pathological effects of the tumor.
The second group of suitable patients is known in the art as the "adjuvant group". These are individuals who have a history of cancer but have been responsive to another treatment modality. Previous therapies included (but are not limited to) surgical resection, radiotherapy and conventional chemotherapy. As a result, these individuals do not have clinically measurable tumors. However, they are suspected of being at risk for disease progression near the original tumor site or by metastasis.
This group can be divided into high risk and low risk individuals. This segmentation is based on the characteristics observed before or after the initial treatment. These features are known in the clinical art and are suitably defined for different cancers, respectively. Typical features of the high risk subgroups are those whose tumors have invaded neighboring tissues or are accompanied by lymph nodes.
Another suitable group of patients are those who have a genetic predisposition to cancer but have not yet demonstrated clinical signs of cancer. For example, a woman who appears to be positive for genetic mutations associated with breast cancer but who is still of childbearing age may wish to be treated with TRRE inhibitors prophylactically to prevent the invention of cancer until suitable for preventive surgery. have.
The pharmaceutical TRRE inhibitor composition embodied in the present invention is administered to patients in either the adjuvant group, or any of these subgroups, to induce an anticancer response. Ideally, the composition delays the recurrence of cancer, or better, reduces the risk of relapse (ie, improves healing rate). These variables can be determined compared to other patient groups and other treatment modalities.
Of course, crossovers occur between these two patient groups, and the pharmaceutical compositions of the present invention can be administered at any suitable time. For example, treatment may be done prior to or during conventional treatment of patients with high tumor burden and may continue until the tumor is clinically undetectable. Treatment may continue to patients who initially entered the adjuvant group but showed signs of relapse. The attending physician can determine when and how the compositions of the present invention will be used.
The invention also includes a method of diagnosing a disease associated with high levels of TRRE by obtaining a biological sample from a patient, measuring the activity of TRRE in the sample and comparing the activity with that of a control biological sample. In the case of cancer diagnosis, increased levels of TRRE activity compared to the control may indicate that cancer is present. In the case of monitoring disease progression or recurrence, the measurement of TRRE can indicate the condition of the disease and can be an early marker of development.
Provided herein, the treatment, diagnosis, and monitoring of cancer include any cancer of the art. These include but are not limited to glioblastoma, melanoma, neuroblastoma, adenocarcinoma, soft tissue sarcoma, leukemia, lymphoma and cancer. The present invention is specifically useful for the treatment, diagnosis and monitoring of cancer. Cancers include astrocytoma, oligodendrosis, supercytosis, medulloblastoma, primitive ectodermal tumor, pancreatic ductal carcinoma, bovine and large cell lung adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, epithelial adenocarcinoma and its liver metastases, liver cancer, cholangiocarcinoma, ducts And lobular carcinoma, squamous and adenocarcinoma of the cervix, epithelial cell carcinoma of the uterus and ovary, prostate adenocarcinoma, transitional squamous cell bladder cancer, B and T cell lymphoma (lobe and diffuse), plasmacytoma, acute and chronic leukemia, malignant melanoma, soft tissue Includes but is not limited to sarcomas and leiomyomas.
As specified in the present invention, there is a composition consisting of a polynucleotide having a therapeutically relevant genetic sequence as an active ingredient. Polynucleotides can be administered, for example, to increase or decrease the natural level of expression of TRRE in target cells.
In another approach to delay TRRE activity, polynucleotides encode an antibody (or fragment thereof) capable of binding to TRRE (or fragment thereof). The polynucleotide will be introduced into the cell and then expressed to produce an antibody or antibody fragment, which then acts as described above to bind to TRRE and regulate its activity.
Polynucleotides to enhance or reduce TRRE expression can be introduced into cells as part of any suitable delivery excipient known in the art. The polynucleotide can be administered to the cell and preferably injected into the tissue site as naked DNA in a structure of supercoil. It is generally preferred to administer the polynucleotide as part of a composition that enhances expression of the target cell. The components of the composition protect the polynucleotide until delivery to the cell and enhance ubiquity or binding thereon near the stromal cells, enhance uptake or endocytosis into the cell, and reposition the polynucleotide into the cytoplasm across the membrane. Or to enhance the transport of polynucleotides within the cell to the site of action.
In one embodiment, the composition consists of half of the ligand-receptor binding pairs and the other half is on the surface of the target cell. This can promote localization near the cell surface and can promote endocytosis into cells or homing to cells in vivo, or a combination thereof. Suitable components for inclusion in the composition include antibodies or antibody fragments specific for the target tissue (eg, tumor associated antigens), integrin and integrin ligands that are selectively specific for the target tissue, and ligands for cytokine receptors on the target tissue. Including but not limited to these. If the aim is to reduce TNF-R levels in target cells by enhancing TRRE expression, a particularly preferred ligand is TNF itself. In this way, the composition will be concentrated towards cells with the phenotype to be treated in preference to other cell types and already effectively treated cells.
In another embodiment, the composition consists of a delivery vehicle that protects the polynucleotide and enhances its delivery to the cell. One type of suitable vehicle is a liposome that encapsulates a polynucleotide or binds it (in the case of a cationic liposome) by charge separation. Another type of suitable vehicle is the capsid or envelope of a virus, conjugated viral particle, or synthetic viral particle that encapsulates or encapsulates the polynucleotide. Preferred of these virus related particles are those that are tropic to the target tissue type and consist of polypeptides (such as influenza hemagglutinin) that promote the fusion and delivery of polynucleotides. The composition may also optionally consist of a genetic element of the virus that facilitates replication of the therapeutic polynucleotide and / or integration of the target cell into the genome. Viral systems suitable for use in the present invention include adenovirus vectors, retrovirus vectors, adeno-associated virus vectors, sindbisvirus vectors, and the like. Preferred are vectors that contain the viral genetic elements required for cis for packaging, the genetic elements required for replication or integration of the therapeutic polynucleotide, but not other viral genetic elements. Such vectors can be produced by a packaging system in which viral elements only required in trans are supplied by a host cell or a second virus. See Flotte et al., WO 95/13365.
It is often desirable to combine these components and strategies into compositions with therapeutic polynucleotides. For example, the polynucleotide may be encapsulated in an adenovirus vector that expresses a target molecule such as TNF as part of a viral package. The vector may alternatively also express a binding molecule, such as an avidin binding site, which may then be bound to biotin-TNF for the purpose of targeting the target cell.
The following examples are meant to illustrate the claimed invention and not to limit the invention.
Example 1: Materials and Methods
Cell lines and reagents:
COS-1, a monkey kidney fibroblast-like cell line, was obtained from the American Type Culture Collection (ATCC) (Rockville, MD) and heated to inactivate 10% fetal calf serum (FCS) (Irvine Scientific, Santa Ana, Calif.) In this added RPMI-1640 medium (GIBCO Laboratories, Grand Island, NY) it was maintained as a sticky monolayer and passaged twice weekly. The cells were maintained at 37 ° C. in a humidified atmosphere of 5% CO ₂ . Transformed COS-1 cell line, designated C75R, was maintained in the same medium with 600 μg / ml of Geneticin (Geneticin, G418-sulphate) (GIBCO BRL Life Technologies, Gaithersburg, MD) and twice weekly Passed. The human monocyte leukemia cell line THP-1 was obtained from ATCC and maintained as suspension culture in RPMI-1640 medium to which 10% heat-inactivated FCS was added. PMA was purchased from Sigma Chemicals, St. Louis, Mo. Recombinant forms of human soluble p55 and p75 TNF-R and TNF were provided by Synergen Inc., Boulder, CO.
ELISA analysis was performed by the following methods: Techniques described by Yamamoto et al. For polyclonal antibodies against human p75 TNF-R and New Zealand white female rabbits [Yamamoto et al. (1978) Cell. Immunol. 38: 403-416]. IgG fractions of immunized earthen serum were determined by E. et al. (1978) Immunochemistry 15: 429-436, using Protein G (Pharmacia Fine Chemicals, Uppsala, Sweden) affinity column. The IgG fraction was then purified by Tijssen and Kurstok, (1984) Anal. Biochem. 136: 451-457] was labeled with horseradish peroxidase.
ELISA for p75 TNF-R was performed as follows: First, 5 μg of unlabeled IgG in 100 μl of 0.05 M carbonate buffer (pH 9.6) was added to a 96-well ELISA microplate (Corning, Corning, NY). ) Was incubated overnight at 4 ° C. Individual wells were washed three times with 300 μl of a 0.2% Tween-20 solution in phosphate buffered saline (PBS). 100 μl of sample and recombinant receptor standard were then added to each well and incubated at 37 ° C. for 1-2 hours. The wells were then washed in the same manner, 100 μl horseradish peroxidase-labeled IgG was added and incubated at 37 ° C. for 1 hour. The wells were washed once more and 30% H ₂ O ₂ (Fisher Scientific, Fair Lawn, NJ) and substrate 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid prepared according to the manufacturer's instructions The color was developed for 20 minutes using diammonium salt (ABTS) (Pierce, Rockford, IL). The results were obtained by measuring absorbance at 450 nm using an EAR 400AT plate reader (SLT-Lab Instruments, Salzburg, Austria). The concentration of sTNF-R in each sample was calculated from the regression line calculated by known standards. Most of the R2 values of the linear regression were greater than 0.99. Dual wells of each dilution or sample were tested and the average of the results recorded.
The following experiment was performed to induce the secretion of TRRE from THP-1 cells. THP-1 cells growing in logarithmic phase were collected and resuspended in RPMI-1640 medium containing 1% FCS at a density of 1 × 10 ⁶ cells per ml of medium at 10 ⁻⁶ M Incubate with PMA for 30 minutes at 37 ° C. in 5% CO ₂ . Cells were collected and washed once with serum free medium to remove PMA and then resuspended in the same volume of RPMI-1640 medium with 1% FCS added. After 2 hours incubation at 37 ° C. in 5% CO ₂ , the cell suspension was collected, centrifuged and the cell-free supernatant collected as a TRRE-containing sample.
The level of TRRE activity in the collected TRRE-1 supernatants was detected and quantified as described and then measured in a novel assay system, which will be described in detail herein below. Briefly, C75R and COS-1 cells were planted in a 24-well culture plate at a density of 2.5 × 10 ⁵ cells / ml / well and incubated for 12-16 hours at 37 ° C. in 5% CO ₂ . The medium in the wells was aspirated off and 300 μl of TRRE test samples were incubated with C75R and COS-1 cells for 30 minutes at 37 ° C. in 5% CO ₂ . At the same time, C75R was incubated with 300 μl of fresh medium or buffer. At the end of the incubation period, samples were collected from each well to determine the level of soluble p75 TNF-R by ELISA. Background levels of sTNF-R measured by incubating TRRE test samples with COS-1 cells and spontaneous release of receptors by C75R measured by incubating medium or buffer with C75R cells alone were incubated with C75R. Total TRRE activity was calculated by subtracting from the levels measured by TRRE experimental samples.
Example 2 In Vitro TRRE Analysis System
The purpose of this study was to establish an analytical system for measuring TRRE activity on its natural form of human TNF-R incorporated into cell surface membranes. Transformed COS-1 cell lines were selected for the assay system because no background of endogenous p75 TNF-R was observed. Attempts to study and characterize enzymes that contribute to sTNF-R release have been difficult because the presence of inactive forms of proteolytic enzymes is indirectly manifested only by the production of soluble receptors. Studies on the release of TNF-R as well as other membrane binding proteins were performed by measuring levels of soluble counterparts for the presence or absence of surface antigens by ELISA or by FACS analysis. Therefore, the level of the enzyme itself has not yet been quantified. Therefore, the inventors have devised a new analysis system for detecting and quantifying TRRE. The release level of the soluble form released into the medium was found to depend on the expression level of the surface antigen on the membrane and the rate at which cells can synthesize more of these proteins and express on the membrane. Some studies have shown that the enzyme levels and the kinetics of the active enzyme formed are related to the levels of the released soluble form and the release kinetics of the soluble form. We have now devised a more defined analytical system for detecting and also quantifying enzymes that specifically cleave TRRE and membrane cleavage proteins in general.
Membrane-bound TNF-R was chosen as the substrate for TRRE instead of recombinant TNF-R molecules, because membrane-bound TNF-R stimulated the substrate with a more physiological microenvironment to assess TRRE activity. Membrane-bound TNF-R may also help to mitigate nonspecific cleavage by other proteolytic enzymes that may occur in non-membrane-bound forms. Because most human cells express only two very low levels of TNF-R, human p75 TNF-R-overexpression is achieved by transforming cDNA into monkey COS-1 cells that do not express any form of TNF-R. Cells were constructed.
The cDNA of human p75 TNF-R was cloned from a λgt 10 cDNA library derived from human monocyte U-937 cells (Clontech Laboratories, Palo Alto, Calif.). CDNA was then subcloned to the EcoRI site of mammalian expression vector pCDNA3 (Invitrogen, San Diego, CA) containing neomycin-resistant genes for selecting transformed cells in the presence of G418. This construct was transformed into COS-1 cells using the calcium phosphate-DNA precipitation method described by Chen and Okayajan. After 24 hours, transformed cells were placed in 600 μg / ml of G418 (GIBCO BRL Life Technologies, Gaithersburg, MD) to select clones that were resistant to neomycin. The cells showing resistance were pooled and named C75R. These cells expressed approximately 70,000 receptors per cell according to Scatchard analysis.
The first 300 bp of both 5 'and 3' ends of the cloned fragments were sequenced and compared to the reported cDNA sequence of human p75 TNF-R. The cloned sequence was a 2.3 kb fragment covering 2380 at position 58 of the reported p75 TNF-R sequence and included the full length of the p75 TNF-R-coding sequence at positions 90-1475. 2.3 kb of p75 TNF-R cDNA was then subcloned into multiple cloning sites of the pCDNA3 eukaryotic expression vector. The orientation of the p75 TNF-R cDNA was confirmed by restriction endonuclease mapping. PCDTR2, the final 7.7 kb construct, included a neomycin-resistant gene for selection of transformed cells in G418, and expression of p75 TNF-R was induced by the cytomegalovirus promoter (FIG. 1). PCDTR2 was then transformed into monkey kidney COS-1 cells using calcium phosphate-DNA precipitation. Clones selected from G418 were named C75R, identified and subcultured.
¹²⁵ I to ICN Pharmaceuticals, Inc. Human prepared TNF, purchased from (Costa Mesa, Calif.), Was radiolabeled using the chloramine-T method. To measure the expression level of p75 TNF-R on C75R cells, 2 × 10 ⁵ cells per well were plated in 24-well culture plates and incubated at 37 ° C. in 5% CO ₂ for 12-16 hours. Wells were then incubated for 2 hours at 4 ° C. with 2-30 ng of ¹²⁵ I radiolabeled human recombinant TNF in the presence or absence of over 100-fold unlabeled human TNF. After washing three times with ice-cold PBS, cells were lysed with 0.1 N NaOH and radioactivity was measured on a Pharmacia Clinigamma counter (Uppsala, Sweden). To determine the effect of TRRE on the surface level of p75 TNF-R, cells were incubated at 37 ° C. for 30 minutes with or without TRRE-containing supernatant, followed by aspirating off the medium followed by radiolabeled TNF. Incubated.
Soluble p75 TNF-R was generated from C75R cells by incubating C75R cells with TRRE-containing supernatant. After incubation for 30 minutes, the supernatants were collected and concentrated by centrifugal force using a Centriprep-10 filter (10,000 MW cut-off membrane) (Amicon, Beverly, Mass.) And subjected to 10% acrylamide SDS-PAGE. The protein was then transferred to a polyvinylidene difluoride membrane (Immobilon) (Millipore, Bedford, Mass.) By electrophoresis. Immunostaining was performed using the Biotin-Streptavidin system (Amersham, Amersham, UK) and the Peroxidase Substrate Kit DAB (Vector Laboratories, Burlingame, Calif.).
The results obtained are shown in FIG. 2, where C75R showed very high levels of specific binding of radiolabeled ¹²⁵ I-TNF, whereas parental COS-1 cells did not. The number of TNF-Rs expressed on C75R was determined to be 60,000 to 70,000 receptors per cell by Scatcher analysis (FIG. 2, inset). The expression level of TNF-R in this clone was 40-50 times higher than that of THP-1 cells. The Kd value calculated from the TNF binding analysis of C75R was 5.6 × 10 ⁻¹⁰ M. Therefore, transformed COS-1 cells expressed high levels of human p75 TNF-R in a form believed to be similar to native TNF-R.
To determine the effect of TRRE on membrane-bound TNF-R, the following experiment was performed. C75R cells were planted in 24-well cell culture plates at a density of 2 × 10 ⁵ cells per well and incubated in 5% CO ₂ at 37 ° C. for 12-16 hours. The medium in the wells was aspirated off and the fresh medium was incubated at 37 ° C. for 30 minutes alone or by replacement with TRRE medium. Throughout this experiment "TRRE-medium" was collected by stimulating THP-1 cells with PMA and then incubating the cells for 2 hours in fresh medium as described. After this incubation, the medium was exchanged with fresh medium containing 30 ng / ml of ¹²⁵ I-labeled TNF. After 2 hours at 4 ° C., the cells were lysed with 0.1 N NaOH and bound radioactivity levels were measured. Specific binding levels of C75R by ¹²⁵ I-TNF were significantly reduced after incubation with TRRE. Radioactivity count was 1,393 cpm for cells incubated with TRRE compared to 10,567 cpm for cells not treated with TRRE, with a 87% binding capacity lost.
To determine the size of p75 TNF-R removed from C75R by TRRE, the following experiment was performed. 15 × 10 ⁶ C75R cells were planted in 150 mm size cell culture plates and incubated at 37 ° C. in 5% CO ₂ for 12-16 hours. TRRE media was incubated with C75R cells in a 150 mm plate for 30 minutes, after which the resulting supernatant was collected and centrifuged. The concentrated sample was subjected to 10% acrylamide SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Immobilon) by electrophoresis. Immunostaining showed a single band of 40 kDa, which was similar in size to that found in biological fluids (FIG. 4).
The following methods and assays were used throughout this experiment to determine TRRE activity. C75R cells and COS-1 cells were planted in a 24-well culture plate at a density of 2.5 × 10 ⁵ cells / ml / well and incubated overnight at 37 ° C. in 5% CO ₂ (12-16 hours). The medium in the wells was aspirated off and 300 μl of TRRE medium was incubated at 37 ° C. in 5% CO ₂ for 30 minutes in each well of both C75R and COS-1 plates (corresponding to A and C mentioned below, respectively). ). At the same time C75R cells in 24-wells were also incubated with 300 μl of fresh medium or buffer (corresponding to B mentioned below). Supernatants were collected, centrifuged and analyzed for concentration of soluble p75 TNF-R by ELISA as described above.
The following values were assigned and formulated. A = (amount of soluble p75 TNF-R in C75R plates treated with TRRE containing samples); The total amount of sTNF-R in the C75R plate. B = (amount of soluble p75 TNF-R naturally released in C75R plates containing the same reagents as the corresponding samples but without exogenous TRRE or treated with buffer only); Ie spontaneous release of sTNF-R from C75R cells. C = (amount of soluble p75 TNF-R in COS-1 plate treated with TRRE sample or background level of soluble p75 TNF-R released by THP-1); Ie the degraded value of (existing) sTNF-R delivered in the TRRE sample during 30 min incubation in COS-1 plate. This corresponds to the background level of sTNF-R digested in C75R plates.
The overall release of soluble p75 TNF-R produced only by TRRE activity present in the initial sample is calculated as follows: (total release of soluble p75 TNF-R made only by TRRE) = A-B-C. The total release of soluble p75 TNF-R was assigned as the amount of TRRE activity and 1 pg of soluble p75 TNF-R total release (ABC) was defined as 1 unit (U) of TRRE activity.
Once the TRRE assay was devised, the time course of receptor shedding was analyzed by the following method. TRRE-medium was incubated with C75R and COS-1 cells for various lengths of time between 5 and 90 minutes. Supernatants were then collected to analyze the levels of soluble p75 TNF-R by ELISA, and total TRRE activity was calculated as described above. Detectable levels of soluble receptors were released by TRRE within 5 minutes, increasing this amount by 30 minutes (FIG. 5A). Subsequent experiments with longer incubation times resulted in a relatively constant TRRE level after 30 minutes, presumably because the substrate was depleted (FIG. 5B). Therefore, 30 minutes was determined as the optimal incubation time for this assay system.
Binding assays showed that parental COS-1 cells did not bind to human ¹²⁵ I-TNF, whereas transformed C75R cells showed strong specific binding. Scatcher analysis showed that the levels of 70,000 receptors per cell were 40-50 times higher than those typically found on other cell lines. This higher level of substrate makes it possible to detect TRRE activity with much higher sensitivity than other cell lines. The Kd value calculated from the Scatcher analysis was 5.6 × 10 ⁻¹⁰ M, which was similar to the value previously reported for native human p75 TNF-R. Therefore, the transformed cell could provide the membrane form of the receptor in its native form, and as a result, could be an excellent substrate source.
When C75R cells were incubated with TRRE medium, soluble p75 TNF-R was released into the supernatant and thus measurable by ELISA. The amount of receptor released corresponded to the TRRE activity level. Since C75R cells were incubated with TRRE medium, other wells of C75R cells were incubated with medium or buffer to determine the level of spontaneous release by C75R. Spontaneous release may be due to endogenous sources of proteolytic enzymes that are homologues of human TRRE of monkey origin. In addition, TRRE medium was incubated with parental COS-1 cells to detect levels of existing soluble receptors in the sample. For this purpose, rather than directly measuring the level of soluble receptors in the supernatant by ELISA, we incubated the sample with COS-1 cells, because we used it for 30 minutes with COS-1 cells. After incubation we observed that the soluble receptors were significantly degraded. The level of early soluble receptors in the supernatant may decrease by 50% after 30 minutes of incubation with COS-1 cells. Two sources of these background soluble receptors were combined to create the most accurate method of calculating total TRRE activity.
The premise that the increase in soluble receptor levels in supernatants is due to proteolytic cleavage of membrane bound receptors is also supported by the loss of binding of ¹²⁵ I-labeled TNF to C75R cells after incubation with TRRE. It became. Since the receptors produced by TRRE are similar in size to those found in biological fluids, this has strengthened the discovery that TRRE produces sTNF-R in vivo.
Example 3 Mechanism of TRRE Generation
In Example 2, a novel assay system was used to detect and quantify the proteolytic activity of TRRE. Using this assay system, (a) PMA demand, (b) FCS dependency, (c) universality in cell lines and monocytes other than THP-1, (d) time course for secretion, (e) TRRE secretion, and The mechanism of TRRE production was further studied, including the effect of PMA on synthesis, and (f) physiological inducers other than PMA.
THP-1 (human monocyte leukemia cell line), U-937 (human histoblast lymphoma cell line), HL-60 (human promyelocytic leukemia cell line), Raji (human Burkitt lymphoma cell line), and K grown in suspension -562 (human myeloid leukemia cell line), adhesively grown ME-180 (human epidermal carcinoma cell line), and MRC-5 (human lung fibroblast cell line) were collected from the American Type Culture Collection (ATCC, Rockville, MD). These cell lines were passaged twice a week in RPMI-1640 / 10% heat-inactivated FCS.
Mononuclear cells were obtained at the interface of an isotonic picol cushion (gravity, 1.05) from Leukopac obtained from normal healthy volunteers according to the manufacturer (Sigma). The monocytes were then isolated by reverse flow centrifugation elutriation using a Beckman JE-5.0 system. On average, the purity of monocyte fractions was greater than 95% as determined by morphological examination and nonspecific esterase staining, and the viability was greater than 98% as assessed by trypan blue dye extraction test.
RPMI-1640 containing 1% FCS at a density of 1 × 10 ⁶ cells per ml of medium for THP-1 cells and human peripheral blood monocytes at 10 ⁻⁸ , 10 ⁻⁷ and 10 ^-6 M PMA for 30 min. Stimulated at 37 ° C. in 5% CO ₂ . Stimulated cells were washed with serum-free medium and resuspended in 37% of 5% CO ₂ in an equal volume of PMA-glass medium with 1% FCS added. Culture supernatants were then collected and analyzed for TRRE activity.
THP-1 cells and human monocytes were stimulated with 10 ⁻⁸ , 10 ⁻⁷ and 10 ⁻⁶ M PMA and each supernatant was analyzed for TRRE activity as described above. ^10-6 M of PMA consistently and strongly stimulated THP-1 cells and human monocytes and induced TRRE release at concentrations of 1,304 and 883 U / ml, respectively (see Table 1). PMA stimulation of 10 ⁻⁷ M induced relatively low amounts of TRRE, and 10 ⁻⁸ M PMA stimulation did not induce any TRRE from monocytes or THP-1 cells (data not shown). PMA stimulation at 10 ⁻⁶ M concentration was adopted in all subsequent experiments to induce TRRE from THP-1 cells.
cellActivatorTRRE active (U) Human montagePMA 10 ^-7 M10 ^-6 M51883 THP-1PMA 10 ^-7 M10 ^-6 M3681,304
Suspension cell lines containing THP-1, U-937, HL-60, Raji and K-562 at a density of 1 × 10 ⁶ cells / ml with 10 ⁻⁶ M PMA in RPMI-1640 / 1% FCS Stimulated at 37 ° C. in 5% CO ₂ for 30 minutes. After pelleting the cells and daughtering the supernatant, the cells were washed once with serum-free medium and then in PMA-free RPMI-1640 / 1% FCS at the same density of 1 × 10 ⁶ cells / ml for at least 2 hours. Incubated. Sticky cell lines, including ME-180 and MRC-5, were placed at 37 ° C. in 5% CO ₂ in a 100 mm cell culture plate containing RPMI-1640 / 10% FCS at a density of 6 × 10 ⁶ cells / 10 ml / plate. Seeding overnight at. After depriving the medium in a 100 mm plate, these adherent cells were immersed in 5% CO ₂ for 30 minutes with 10 ⁻⁶ M PMA (approximately 1 × 10 ⁶ cells / ml) in 6 ml of RPMI-1640 / 1% FCS. Stimulated at 37 ° C. After washing the plate three times with serum free medium, cells were incubated in 6 ml of PMA-free RPMI-1640 / 1% FCS for at least 2 hours. These supernatants from the suspension and adherent cells were collected and analyzed for TRRE activity (as described in Example 1).
10 ^-6 M PMA-stimulated suspensions including THP-1, U-937, HL-60, Raji, and K-562 and sticky cell lines containing ME-180 and MRC-5 were each 1 × 10 ⁶ cells TRRE activity was induced at concentrations of 2,884 U / ml, 3,288 U / ml, 3,144 U / ml, 2,390 U / ml, 3,356 U / ml, 1,694 U / ml, and 1,477 U / ml (Table 2). Therefore, TRRE can be induced by THP-1 cells as well as by all cell lines studied using PMA-stimulation.
Cell lineTRRE (U / ml / 10 ⁶ cells) THP-1 (human monocyte leukemia)2,884 U-937 (Human Tissue Lymphoma)3,288 HL-60 (human promyelocytic leukemia)3,144 ME-180 (human epidermal carcinoma)1,694 MRC-5 (human lung fibroblast)1,477 Raji (Brukitt lymphoma)2,390 K-562 (human myeloid leukemia)3,356
THP-1 cells were stimulated with 10 ⁻⁶ M PMA for 30 minutes in RPMI-1640 with 1% FCS. Stimulated cells were then washed and incubated in PMA-free RPMI-1640 with 0%, 1% and 10% FCS for at least 2 hours, resulting in induction of TRRE of 224, 1,356 and 2,275 U / ml, respectively. (Table 3). This suggests that some serum factors are needed for the cell to respond normally to PMA.
FCS concentrationTREE active (U / ml) 0 %224 One %1,356 10%2,275
THP-1 cells were stimulated with 10 ^-6 M PMA for 30 minutes in RPMI-1640 with 1% FCS, then washed and resuspended in the same volume of PMA-glass medium with 1% FCS. It was. The cells were further incubated for 2 to 23 hours so that the total induction time of TRRE from the initial stimulation was 3 to 24 hours. This epidemiologic study showed that the release of TRRE into the culture supernatant was highest in the first 3 hours and then gradually decreased, whereas the level of sTNF-R derived from THP-1 cells increased over time (FIG. 6). As a result, 2 hours incubation (total 3 hours induction) was adopted in subsequent experiments to achieve higher TRRE activity while lowering the sTNF-R background.
TRRE medium was serially diluted to 1: 256 dilution. Detectable levels of TRRE activity were also present in samples diluted 16-fold (FIG. 7). While the level of sTNF-R present in the TRRE supernatant decreased in proportion to its dilution rate, there was no significant difference in TRRE activity when comparing the original supernatant with the 2-fold diluted supernatant, which depleted the substrate. And the level of TRRE activity in the original supernatant would have satisfied the assay system.
Cycloheximide (Chx) (inhibitor of protein synthesis), Actinomycin D (ActD) (inhibitor of RNA synthesis), N-ethylmaleimide (NEM) (inhibitor of membrane internalization and migration), cytocalin B (CytB Several inhibitors were purchased from Sigma Chemical, St. Louis, MO, including (inhibitors of microfilament formation), and colchicine (inhibitors of microtubule formation). THP-1 cells at 1 × 10 ⁶ cells / ml density in RPMI-1640 / 1% FCS were loaded with 10 μg / ml Chx, 1 μg / ml ActD, 1 mM NEM, 0.1 mM CytB, and 0.1 mM Stimulated with 10 ^-6 M PMA with Col was stimulated in 5% CO ₂ at 37 ℃ for 30 minutes. After centrifugation at 400 × g for 5 minutes, the supernatant was discarded and the cells washed with medium without serum. The cells were then incubated for an additional 2 hours at the same density (1 × 10 ⁶ cells / ml) in PMA-free RPMI-1640 to which the corresponding inhibitors were added. Their supernatants were collected and analyzed for TRRE activity. Supernatants from THP-1 cells stimulated with only 10 ^-6 M PMA and without any inhibitor were used as controls. % TRRE production was expressed by dividing the TRRE activity induced by PMA and inhibitor by the TRRE activity of the control.
To understand the mechanism of PMA acting in TRRE production, various inhibitors were incubated with PMA as described above. 10 μg / ml Chx, 1 μg / ml ActD, 1 mM NEM, 0.1 mM CytB, and 0.1 mM Col exhibited 104%, 97%, 17%, 91%, and PMA-induced TRRE activity, respectively. Modified to 111% (Table 4). The results obtained indicate that NEM alone inhibited PMA-induced TRRE activity, suggesting that membrane internalization and migration are only involved in the release of PRE induced by PMA. Protein synthesis, RNA synthesis and delivery in the cytoplasm are unlikely to be required for PMA-induced TRRE release.
Inhibitordensity% Of TRRE generation Actinomycin D1 μg / ml104 Cycloheximide10 μg / ml97 N-ethylmaleimide1 mM17 Cytokalcin B0.1 mM0.01 mM91103 Colchicine1 mM 0.1 mM 0.01 mM12511195
THP-1 cells at 1 × 10 ⁶ cells / ml density were stimulated with 10 ⁻⁶ M PMA in 1% FCS-containing RPMI-1640 in 5% CO ₂ at 37 ° C. for 30 minutes. Cells were washed with medium without serum to remove PMA, and then cells were incubated in 5% CO ₂ for 2 hours at 37 ° C. in the same volume of 1% FCS-containing RPMI-1640 without PMA. Cells were then centrifuged and the supernatant collected for TRRE analysis. These pelleted cells were again resuspended in 1% FCS-containing RPMI-1640 with or without ^10-6 M of PMA and incubated in 5% CO ₂ at 37 ° C. for 30 minutes. After washing the cells with serum-free medium to remove PMA, cells stimulated or unstimulated by PMA were removed for 5 hours at 37 ° C. for 2 hours and 4 hours at 37 ° C., respectively, in the same volume of 1% FCS-containing RPMI-1640 without PMA. Incubate in% CO ₂ . Then, all four types of supernatants were collected for TRRE analysis (performed as in Example 1).
THP-1 cells were stimulated twice with PMA to study the continuous induction of TRRE as described. By the first stimulation of PMA, THP-1 cells released 951 U / ml of TRRE. These cells were then stimulated again by PMA for 30 minutes and further incubated for 2 and 4 hours in medium without PMA, releasing 1,245 U / ml and 1,044 U / ml of TRRE, respectively (FIG. 8). . On the other hand, after the first stimulation with PMA, THP-1 cells were again incubated in medium without PMA for 2 and 4 hours and then incubated and washed for 30 minutes in medium without PMA, which did not release TRRE activity. . These data showed that TRRE could be released again by incubating a second stimulus with nearly equal concentrations of PMA and incubating for 2-4 hours, whereas no new TRRE release was detected once there was no second PMA stimulation once stimulated with PMA. Indicated. According to these data, the response of THP-1 cells to PMA for the release of TRRE can be very fast, but the response does not last more than 2 hours once PMA is removed.
THP-1 cells at 1 × 10 ⁶ cells / ml density with 1% FCS-containing RPMI-1640 alone for 2 hours, or IL-1β (10 ng / ml), IL-2 (4 μg / ml), IL- 4 (10 ng / ml), IL-6 (100 ng / ml), IL-10 (100 ng / ml), TNF (1 μg / ml), LT (1 μg / ml) and IFN-γ (100 ng / ml), and hormones including epinephrine (10 ^-6 M), insulin (10 ^-7 M), prostaglandin E ₂ (PGE ₂ ) (10 ^-7 M) and hydrocortisone (10 ^-6 M) Stimulated in this added medium. After pelleting the cells, the culture supernatants were collected and analyzed for TRRE activity. Spontaneous release levels of soluble p75 TNF-R for TRRE analysis were obtained by incubating C75R cells in RPMI-1640 / 1% FCS containing exogenous stimulants without exogenous TRRE.
We found that PMA is a very potent and rapid inducer of sTNF-R [Gatanaga et al. (1991); And Hwang et al. (1993), J. Immunol. 151: 5631-5638. However, various cytokines and hormones were studied as described above to determine physiological inducers of TRRE other than PMA. Epikines, including cytokines including IL-1β, IL-2, IL-4, IL-6, IL-10, TNF, LT, and IFN-γ, and hormones including epinephrine, insulin, PGE ₂ and hydrocortisone IL-10 induced TRRE activity by 2 hour stimulation. The level of TRRE activity induced by IL-10 and epinephrine was significantly lower than that induced by PMA.
Tables 1 and 2 indicated that the TRRE induction protocol and its assay system were effective not only for all tumor cell lines studied, but also for normal human monocytes. Therefore, TRRE activity is probably not a feature unique to transformed cell lines, but a feature that most human cells have. This is consistent with previous reports that most human cells express both TNF-Rs simultaneously (Gehr et al. (1992); Naume et al. (1991), J. Immunol. 146: 3045-3048; And Porteu et al. (1991), J. Biol. Chem. 266: 18846-18853. Therefore, cells can self-regulate their sensitivity to TNF by regulating their number of TNF-Rs by synthesizing TRRE. PMA concentrations as low as 10 ⁻⁶ M needed to observe effective induction of TRRE may be due to the protocol used. In this experiment, THP-1 cells were pulsated for 30 minutes, washed once to remove PMA and incubated for at least 2 hours in media without PMA for induction of TRRE. It is also quite possible for these cells to release high levels of active TRRE immediately after pulsating stimulation with PMA for 30 minutes. TRRE released during this period can be discarded when the cells are washed and incubated with fresh medium.
Although production of TRRE was FCS-dependent, FCS-enriched media alone did not induce TRRE activity without PMA stimulation. Therefore, while some serum factors can assist in the secretion of TRRE induced by PMA, the serum itself does not. Since incubation of PMA stimulated THP-1 cells in the presence of 1% FCS can significantly reduce the level of contaminating protein from FCS and increase the inactivation of TRRE in the supernatant (value of TRRE unit / A280). TRRE induction at 1% FCS was adopted in subsequent experiments.
PMA is an extremely potent and rapid inducer of TRRE, and indirectly with TNF-R. After stimulating THP-1 cells with 10 ⁻⁶ M PMA for 30 minutes, the secretion of TRRE started immediately and quickly reached its maximum within 2 hours. This suggests that TRRE is already stored in THP-1 cells and ready to be secreted in response to PMA-stimulation. Basically, PMA is a potent stimulant of protein kinase C, once immobilized inside activated cell membranes. Therefore, (i) TRRE is stored in the cytoplasm near the cell membrane and is ready to be secreted through the protein kinase C cascade by PMA stimulation; (ii) TRRE is a peripheral (or foreign) membrane protein isolated from the membrane through alteration of interaction with other proteins or any phospholipids by stimulated protein kinase C; Or (iii) TRRE is likely an internal (or native) membrane protein whose cytoplasmic portion is cleaved and secreted in active form after interacting directly or indirectly with protein kinase C.
TRRE induction by PMA did not require new protein synthesis, RNA synthesis and delivery into the cytoplasm, only membrane internalization and migration. This is consistent with data that TRRE is released very quickly by PMA stimulation and is removed once PMA is stopped. However, by PMA stimulation, TRRE synthesis commenced with TRRE release. After initial release, TRRE accumulates within the cell or on the cell surface within 2 hours and is ready to be secreted by the next stimulus. Evidence for the direct cleavage of TNF-R is that shedding of sTNF-R occurs very quickly (5 minutes) and reaches maximum shedding within 30 minutes.
Except for PMA, the shedding of sTNF-R is a variety of cytokines including TNF, IL-1, IL-6, IL-10 and IFN, formyl-methionyl-royyl-phenylalanine (fMLP) and C5a, and It is known to be enhanced by leukocyte migration enhancers, including calcium ionocytes [Gatanaga (1993), Lymphokine Res. 12: 249-253; Porteu (1994), J. Biol. Chem. 269: 2834-2840; van der Poll (1995) J. Immunol. 155: 5397-5401; Porteu (1991); And Porteu and Natah (1990) J. Exp. Med. 172; 599-607. Although IL-10 and epinephrine were not as potent as PMA in the experiments presented in this example, TRRE was induced from THP-1 cells by 2 hour stimulation.
IL-10 is a potential inhibitor of monocyte- and macrophage-functions [Moore (1993) Annu. Rev. Immunol. 11: 165-190. IL-10 has anti-inflammatory activity against monocytes and inhibits the release of pro-inflammatory cytokines including TNF and IL-1 [Bogdan et al. (1991) J. Exp. Med. 174: 1549-1555; Fiorentino et al (1991) J. Immunol. 147: 3815-3822; de Waal Malefyt et al. (1991) J. Exp. Med. 174: 1209-1220; Katsikis et al. (1994) J. Exp. Med. 179: 1517-1527; Joyce et al. (1994) Eur. J. Immunol. 24: 2699-2705; And Simon et al. (1994) Proc. Natl. Acad. Sci. USA 91: 8562-8566. Elevated levels of IL-10 have been detected in the plasma of patients with sepsis and in plasma after administration of LPS to animals [Marchant et al. (1994) Lancet 343: 707-708; Derkx et al. (1995) J. Infect. Dis. 171: 229-232; Durez et al. (1993) J. Exp. Med. 177: 551-555; And Marchant et al. (1994) Eur. J. Immunol. 24: 1167-1171. In vivo, IL-10 has also been shown to protect mice against endotoxin shock [Gerard et al. (1993) J. Exp. Med. 177: 547-550; And Howard et al. (1993) J. Exp. Med. 177: 1205-1208. IL-10 induces increased levels of mRNA for p75 TNF-R, increased release of soluble p75 TNF-R and concomitant decrease in surface expression of p75 TNF-R [Joyce et al. (1994)]. Therefore, IL-10 by (i) inhibiting the release of TNF itself, (ii) down-regulating surface TNF-R expression, while (iii) increasing the production of sTNF-R, which can neutralize TNF cytotoxicity It can be considered to reduce the pro-inflammatory potential of TNF [Joyce et al. (1994); And Leeuwenberg et al. (1994) J. Immunol. 152: 4036-4043. The data of this example showing that IL-10 can induce TRRE activity is consistent with these findings and indicates the newly emerged function of IL-10 as an anti-inflammatory cytokine.
In high-tension situations, including endotoxin shock, serum levels of catecholamines and glucocorticoids are easily elevated from the adrenal medulla and adrenal cortex in response to high serum levels of corticosteroids (ACTH), respectively, throughout the systemic system. TNF is also involved in early metabolic events following stressful situations, and infusion of recombinant TNF in dogs has been associated with increased serum levels of catecholamines, glucocorticoids and glucagon [Tracey et al. (1987) Surg . Gynecol. Obset. 164: 415-422. On the other hand, as a local phenomenon, epinephrine and norepinephrine are found in macrophages expressing β-adrenergic receptors, and these endogenous catecholamines are believed to regulate LPS-induced TNF production in a self-secreting mode in vitro. Hjemdahl et al. (1990) Br. J. Clin. Pharmacol. 30: 673-682; Talmadge et al. (1993) Int. J. Immunopharmacol. 15: 219-228; And Spengler et al. (1994) J. Immunol. 152: 3024-3031. Indeed, the unusual β-adrenergic agonists exogenous epinephrine and isoproterenol inhibit the production of TNF from LPS-stimulated THP-1 cells and human blood [Hu et al. (1991) J. Neuroimmunol. 31: 35-42; And Severn et al. (1992) J. Immunol. 148: 3441-3445.
While epinephrine is an important endogenous inhibitor of TNF production, epinephrine also reduces the number of TNF-Rs on macrophages, especially in sepsis [Bermudez et al. (1990) Lymphokine Res. 9: 137-145. We have shown that in trauma patients both levels of p55 and p75 TNF-R were significantly elevated with high serum levels of epinephrine within 1 hour after injury [Tan et al. (1993) J. Trauma 34: 634-638]. . These findings are consistent with data that epinephrine induced TRRE activity and could lead to an increase in sTNF-R.
Insulin and glucagon have a function of down-regulation of TNF-R in addition to epinephrine (Bermudez et al. (1990)). In addition to IL-10, many inflammatory cytokines have an effect on the shedding of sTNF-R. For example, TNF, IL-1, IL-6 and IFN up-regulation, and IL-4 can affect down-regulation [van der Poll et al. (1995); Gatanaga et al. (1993); And Joyce et al. (1994). According to the data provided in this example, insulin, IL-1β and IL-6 induced sTNF-R from THP-1 cells with 2 hour stimulation but showed no TRRE activity, indicating that sTNF-R is a protein other than TRRE. It can be produced by the enzyme (s) or other forms of TRRE that can be membrane-bound. Therefore, there will be at least two pathways that contribute to the shedding of sTNF-R in vitro as well as in vivo. In vivo, one can be seen in trauma patients who experience a rapid increase in sTNF-R in serum. This pattern of increase is similar to that caused by PMA stimulation and therefore probably mediated by TRRE. Other pathways in vivo are involved in the chronic or natural induction of sTNF-R seen in cancer patients and even healthy individuals [Gatanaga et al. (1990a); And Gatanaga et al. (1990b). Perhaps various TRRE forms, including protease (s) other than TRRE or membrane-bound forms activated in soluble form by cleavage, can contribute to this increase in sTNF-R. However, the induction of sTNF-R in cancer patients will be at least partly due to increased TRRE activity. This activity was generally higher in human lung tumors than in non-cancerous surrounding tissues. As can be seen in FIG. 20, in 9 of 12 cases, TRRE activity was higher in culture supernatants of tumor cells than in culture supernatants of surrounding non-tumor cells. In cases 2, 3, 5, 9 and 11, TRRE activity was approximately 75%, 50%, 30%, 36%, and 60% higher in tumor cells than in non-tumor cells, respectively.
Example 4 Physiological Properties of TRRE
In this example, (a) stability versus temperature and pH, (b) metal requirements, (c) classification of mechanisms of proteolytic enzymes, (d) comparison with known proteolytic enzymes, in particular MMP, and (e) sTNF We studied the physiological properties of TRRE, including the morphological relationship between -R and TRRE. This example further provides a partial purification step for TRRE and the results.
To purify TRRE, TRRE medium was concentrated by 100% saturated ammonium sulphate precipitation at 4 ° C. The precipitate was pelleted by centrifugation at 10,000 × g for 30 minutes and it was resuspended in approximately two volumes of PBS of the pellet. This solution was then dialyzed at 4 ° C. against 10 mM Tris-HCl, 60 mM NaCl, pH 7.0. This sample was pre-equilibrated with anion-exchange chromatography, 50 mM Tris-HCl, 60 mM NaCl, pH 8.0, dimethylaminoethyl (DEAE) -Sepadex A-25 column (Pharmacia Biotech) (2.5 × 10) cm). TRRE was then eluted using 60-250 mM NaCl, 50 mM Tris-HCl, pH 8.0 linear gradient. Each fraction was measured for absorbance at 280 nm and analyzed for TRRE activity. The DEAE fractions showing the highest inactivity (highest value of TRRE unit / A280) were collected and used to characterize the TRRE described in this example. These samples are named "partially purified" TRRE in this example.
Partially-purified TRRE was preincubated with several classes of protease inhibitors at 37 ° C. for 30 minutes. Phenylmethylsulfonyl fluoride (PMSF), 4- (2-aminoethyl) -benzenesulfonyl fluoride (AEBSF), 3,4-dichloroisocoumarin (3,4-DCI), N-αtosyl-L- Lysine chloromethyl ketone (TLCK), N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), ethylenediaminetetraacetic acid (EDTA), ethyleneglycol bis (2-aminoethyl ether) tetraacetic acid (EGTA), 1,10- Proteolytic enzymes, including phenanthroline and phosphoramidone, were purchased from Sigma Chemical (St. Louis, Mo.). These inhibitors can be divided into the following classes: (i) Serine protease inhibitors (4 mM PMSF, 0.5 mM AEBSF, and 0.1 mM 3,4-DCI); (ii) serine and cysteine protease inhibitors (0.1 mM of TLCK and TPCK); (iii) chelating agents (2 mM of EDTA, EGTA, and 1,10-phenanthroline); (iv) metalloproteinase inhibitors (0.5 mM of phosphoramidone); And (v) divalent heavy metal ions (2 mM CaCl ₂ , MgCl ₂ , MnCl ₂ , ZnCl ₂ , CoCl ₂ , CuCl ₂ , and FeCl ₂ ). After the end of the preincubation, the samples were analyzed for TRRE activity. For TRRE analysis, C75R cells were incubated with the corresponding reagent without TRRE so that soluble p75 TNF-R was naturally released from each C75R cells to each sample. Partially-purified TRRE, pre-incubated at 37 ° C. for 30 minutes without any reagents and analyzed for TRRE activity, was taken as a control. Remaining% activity (% control) is shown in comparison to the control.
Partially purified TRRE was analyzed for 4 mM CaCl ₂ , 0.1 mM ZnCl ₂ , 2 mM 1,10-phenanthroline, 2 mM 1,10-phenanthroline and 2 mM CaCl before assaying for TRRE activity. Pre-incubation with ₂ , or 2 mM 1,10-phenanthroline and 2 mM ZnCl ₂ for 30 minutes at 37 ℃. Remaining% activity (% control) was calculated as above.
The obtained results are shown in Table 6. Partial inhibition of TRRE activity was obtained by chelating agents such as 1,10-phenanthroline, EDTA and EGTA (the% TRRE activity remaining at concentrations of 2 mM were 41%, 67% and 73%, respectively), This was a potent inhibitor of metalloproteinases (Table 5). On the other hand, serine protease inhibitors such as PMSF, AEBSF and 3,4-DCI, and serine and cysteine protease inhibitors such as TLCK and TPCK did not affect TRRE inhibition. These data suggest that TRRE requires metal ion (s) for its activity. In order to further evaluate metal requirements of TRRE, enzyme activity was assessed in the presence of divalent metal ions at a concentration of 2 mM. TRRE was slightly activated in the presence of Mn ²⁺ , Ca ²⁺ , Mg ²⁺ , and Co ²⁺ (the remaining% TRRE activities were 157%, 151%, 127% and 123%, respectively), while partial Inhibition occurred in the presence of Zn ²⁺ and Cu ²⁺ (the remaining% TRRE activities were 23% and 47%, respectively) (Table 5).
InhibitorConcentration (mM)% Control of TRRE Activity PMSF4116 ± 4 AEBSF0.592 ± 8 TLCK0.1108 ± 5 TPCK0.1107 ± 7 3,4-DCI0.1108 ± 4 EDTA267 ± 7 EGTA273 ± 4 1,10-phenanthroline241 ± 6 Phosphoramidon0.584 ± 13 Ca ²⁺ 2151 ± 23 Mg ²⁺ 2127 ± 9 Mn ²⁺ 2157 ± 33 Zn ²⁺ 223 ± 15 Co ²⁺ 2123 ± 15 Cu ²⁺ 247 ± 21 Fe ²⁺ 298 ± 8
As can be seen in Table 6 below, with 4 mM Ca ²⁺ and 0.1 mM Zn ²⁺ , TRRE showed 189 ± 4% and 122 ± 6% activity (% remaining TRRE activity), respectively (Table 5 ). However, as can be seen in Table 7, high concentrations (2 mM or more) of Zn ²⁺ partially inhibited TRRE activity. Therefore, Zn ²⁺ has two opposite effects on TRRE activity depending on its form, while Ca ²⁺ can activate TRRE at any concentration. In combination with 2 mM 1,10-phenanthroline, a potent inhibitor of metalloproteinases, TRRE partially inhibited TRRE, and 2 mM of 1, 10 mM Ca ²⁺ or 2 mM Zn ²⁺ was added. TRRE activity inhibited by 10-phenanthroline was partially restored. Therefore, at least Zn ²⁺ and Ca ²⁺ regulate TRRE activity. Since TRRE activity appears to be metal dependent, TRRE can be a metallic protease-like enzyme.
% Control of TRRE Activity Ca ²⁺ (4 mM)189 ± 4 Zn ²⁺ (0.1 mM)122 ± 6 1,10-phenanthroline (2 mM) + Ca ²⁺ (2 mM) + Zn ²⁺ (2 mM)47 ± 980 ± 1562 ± 6
To detect MMP activity, certain portions of crude and partially-purified TRRE samples were slightly modified by Hips et al. [Hibbs et al. (1985) J. Biol. Chem. 260: 2493-2500] by gelatin, casein, elastin, and type I collagen zymography. In brief, these samples are dissolved without boiling in non-reducing Laemry sample buffer and then used an 8% SDS polyacrylamide slab gel containing 1 mg / ml of gelatin, casein, elastin, and type I collagen. Separated by electrophoresis. After electrophoresis, the gel was stirred at room temperature for 30 minutes with 5 mM CaCl ₂ , 1 μm ZnCl ₂ , 50 mM Tris-HCl buffer containing 2.5% Triton X-100 (v / v), pH 7.6. Wash twice with vibration to remove SDS, then simply wash with the wash solution without Triton X-100. Gran gel was then in 37 mM 50 mM Tris-HCl buffer, pH 7.6, containing 5 mM CaCl ₂ , 1 μm ZnCl ₂ , 1% Triton X-100 (v / v), 0.02% NaN ₃ . Incubation was while shaking overnight at ° C. The enzymatic reaction was terminated by addition of 10% acetic acid, stained with 0.1% Cumachi fluorescent blue R-250 and desalted with 10% acetic acid and 10% methanol solution.
In this assay, the apparent contrast on the blue background indicates the presence of gelatin, casein, elastin and type I collagen in gelatin, casein, elastin, and type I collagen zymography, respectively. These MMP activities on zymography were compared to the TRRE activity of the corresponding sample. For four crude TRRE samples, THP-1 cells at a density of 1 × 10 ⁶ cells / ml were stimulated with or without 10 ⁻⁶ M PMA for 30 minutes in 0% or 1% FCS-containing RPMI-1640. The cells were then incubated for at least 2 hours in medium containing the same concentration of FCS and without PMA. Partially-purified TRRE samples were prepared as serum-free TRRE sources as described above. For positive control of MMP, THP-1 cells were incubated for 24 hours with 10 ^-6 M PMA in serum-free RPMI-1640 medium, then the culture medium was washed, and then cells were fresh without PMA. After an additional 24 hours incubation in serum-free medium, supernatants were obtained.
Previously, MMPs have been reported to contribute to cleavage of pro-TNF [Gearing et al. (1994); And Gearing et al. (1995). Since TRRE is believed to be a metalloproteinase, zymography was performed to detect MMP activity in TRRE samples. Zymography on gelatin-, casein-, elastin-, and type I collagen-containing gels primarily results in 72 kD gelatinase A and 92 kD gelatinase B (MMP-2 and MMP-9), straw Melicin (MMP-3) and matrilysine (MMP-7), macrophage metalloelase (MMP-12), and interstitial collagenase (MMP-1) were detected, respectively. These MMPs have been found to be secreted by macrophages [Hibbs et al. (1985); Chin et al. (1985) J. Biol. Chem. 260: 12367-12376; Miyazaki et al. (1990) Cancer Res. 50: 7758-7764; Senior et al. (1991) J. Biol. Chem. 266: 7870-7875; Dansette et al. (1979) Anal. Biochem. 97: 340-345. 10A and 10B show the relationship between TRRE activity and gelatin zymography for crude and partially-purified TRRE samples, respectively. Each is a representative example of four different substrate-implanted zymogen gels. Only PMA-stimulated THP-1 cells in 0% and 1% FCS-containing supernatants produced TRRE at concentrations of 217 and 2,096 U / ml, respectively (FIG. 10A). The latter crude sample containing 1% FCS was treated in the same manner as the enzymatic source of TRRE described above. On gelatin zymography, two gelatin degradation bands derived from gelatin A and B were detected at exactly the same intensity in three 1% FCS-containing samples, indicating that these MMP activities were induced from 1% FCS rather than from TRRE. Indicates. Gelatin degradation activity was not detected in partially-purified TRRE without FCS as opposed to its high TRRE activity (3,514 U / ml) (FIG. 10B). Despite the strong gelatin degradation activity, the positive control lacked TRRE activity. Casein, elastin and type I collagen zymography gels showed no MMP activity in either the crude or partially-purified samples. Therefore, TRRE appears to have a different activity than known macrophage-associated MMPs.
To determine the molecular weight of TRRE by gel filtration, TRRE was obtained from THP-1 cells stimulated with PMA in RPMI-1640 with 1% FCS. This source was adjusted to 100% saturation with ammonium sulfate and the precipitate was pelleted and then resuspended in PBS and dialyzed as described for partial purification. This concentrated TRRE (1 ml) was loaded onto a Sephadex G-150 column (1.0 × 30 cm) (Pharmacia Biotech) equilibrated in 10 mM Tris-HCl, 60 mM NaCl, pH 7.0. The flow rate was 1 ml / min and 1 ml fractions were collected for TRRE activity, soluble p75 TNF-R and absorbance measurements at 280 nm.
The results obtained indicate that TRRE activity was detected as a single peak with similar profile of soluble p75 TNF-R in gel filtration (FIG. 11). Two peak elutions of TRRE and soluble p75 TNF-R took place in fraction number 10, which shifted by approximately 150 kDa molecular weight according to the criteria. The same sample was also subjected to DEAE-Sepadex chromatography to obtain a similar profile between TRRE and soluble p75 TNF-R. This evidence suggests that some of the enzymatic products of TRRE and sTNF-R, TRRE remained bound in the reaction solution and migrated as complexes in both gel filtration and DEAE columns. To ensure that TRRE was specifically purified, affinity chromatography was performed on soluble p75 TNF-R Sepharose Affinity Chromatography on the purified TRRE. The activity of the partially-purified TRRE was adjusted to 5,000 U / ml with 10 mM Tris-HCl, 60 mM NaCl, pH 7.0. This diluted TRRE was incubated with C75R cells growing in the log state in 5% CO ₂ (15 ml TRRE per plate) for 30 minutes at 37 ° C. in a 150 mm cell culture plate. Supernatants (75 ml) obtained from five plates were collected and concentrated to approximately 2 ml by centrifugal force using Centriprep-10 filter (Amicon). This concentrated sample was soluble p75 TNF-R affinity chromatography (soluble p75 TNF-R- and Affigel 10 (Bio-Rad) -conjugated equilibrated with 10 mM Tris-HCl, 60 mM NaCl, pH 7.0. Column) (column size: 1 × 2 cm) was applied directly at 4 ° C. The column was then washed with 10 ml of the same Tris-buffer and eluted with 5 ml of Elution Buffer (ImmunoPure elution Buffer, Pierce). The eluate obtained from the affinity column was subjected to gel filtration (Naps 5 column, Pharmacia) to replace the elution buffer with 10 mM Tris-HCl, 60 mM NaCl, pH 7.0 and fractions of 2 ml were collected. Each fraction was measured for TRRE activity and absorbance at 280 nm. Total TRRE activity obtained from the active fraction of gel filtration was considered as TRRE activity of the eluate of soluble p75 TNF-R affinity chromatography. The flow rate and washing of the affinity column with buffer 10 mM Tris-HCl, 60 mM NaCl, pH 7.0 were measured directly for TRRE activity without gel filtration.
To elucidate the hypothesis that sTNF-R, the combined form of TRRE and its enzymatic product, is also present in vitro, the reaction solution between TRRE and its substrate-expressing C75R cells was described as described above for soluble p75 TNF-R -Applied to affinity column. Of the total amount (100%) of TRRE recovered from the soluble p75 TNF-R-affinity column, 53%, 22% and 25% were distributed during the flow passage, at the wash and at the elution (FIG. 12A). This data means that 25% of the active TRRE can bind to the soluble p75 TNFF-R affinity column once the TRRE has been treated with its substrate and then their binding forms will be present in vivo.
The stability of the partially-purified TRRE was studied for various temperature and pH values. TRRE activity was stable when stored at -70 ° C. TRRE activity, however, was incubated at 4 ° C. for 2 days, heated at 56 ° C. for 30 minutes, and boiled for 15 minutes to decrease 82%, 84% and 16% of initial activity, respectively. TRRE samples were treated at various pH levels and preincubated at 37 ° C. for 30 minutes, after which the pH of all samples was adjusted to 7.4 and then subjected to TRRE analysis. TRRE samples were incubated at pH 6.0, 7.0, 8.0 and 9.0, showing 52%, 100% and 69% ALC 73% of TRRE activity contained in the original supernatant (pH 7.4), respectively (Table 8). Therefore, the optimal pH of TRRE was around 7.0, and its activity was lower in acidic conditions than in basic conditions.
Temperature% Control of TRRE ActivitypH% Control of TRRE Activity 48 hours at 4 ℃826.052 30 minutes at 56 ℃847.0100 15 minutes at 100 ℃168.09.06973
Since TRRE and sTNF-R remain bound in the reaction solution in vitro, their affinity was studied to determine whether these complexes act as inhibitors or protective agents of TRRE in enzymatic reactions. Partially-purified TRRE was incubated with C75R cells growing in log state in 5% CO ₂ at 37 ° C. for 30 minutes in a 150 mm cell culture plate. TRRE activity was analyzed before and after treatment with the culture plate. During incubation the substrate (TNF-R) was considered to be much more than the enzyme (TRRE). Relative to TRRE activity before the reaction, 86% of TRRE activity was detected even after the reaction (FIG. 12B). Therefore, even though TRRE activity was treated with excess substrate, thereby creating conditions in which high concentrations of TRRE / sTNF-R complexes were present, TRRE activity remained relatively high for the total reaction. Therefore, this TRRE / sTNF-R complex form did not inhibit TRRE.
Due to the metal requirements of TRRE indicated by the effects of chelating agents and divalent heavy metal ions, TRRE is considered to be a metallic proteolytic enzyme. The reason for the incomplete inhibition by the chelating agent may be because TRRE partially purified from DEAE-Sepadex chromatography also consists of several other enzymes or factors that affect the cleavage of TNF-R. Another explanation is that the concentrations of chelating agent and divalent metal ions needed to achieve complete inhibition were not obtained due to their toxicity to C75R cells in this assay system. Inhibition of this TRRE activity by 1,10-phenanthroline has been independently partially restored by Ca ²⁺ and Zn ^2+, this number of the metal ion, the activity of TRRE including Ca ²⁺ and Zn ²⁺ Or stability. Both records demonstrate the incorporation of metallic proteolytic enzymes into the production of sTNF-R by utilizing the specific metallic protease inhibitor TNF-α protease inhibitors (TAPI).
TAPI blocks shedding of soluble p75 and p55 TNF-R, respectively [Crowe et al. (1995); And Mullberg et al. (1995). Moreover, the processing of pro-TNF on the cell surface has been reported to depend on MMP-like enzymes [Gearing et al. (1994); And Gearing et al. (1995). MMP is a family of structurally related matrix-degrading enzymes that play an important role in tissue composition and development and repair associated with inflammatory responses [Matrisian (1990) Trends Genet. 6: 121-125; Woessner (1991) FASEB J. 5: 2145-2154; And Birkedal-Hansen et al. (1993) Crit. Rev. Oral Biol. Med. 4: 197-250. Pathological expression of MMPs causes tumor invasion, osteoarthritis, atherosclerosis, and emphysema [Mignatti et al. (1986) Cell 47: 487-498; Khokha (1989) Science 243: 947-950; Dean et al. (1989) J. Clin. Invest. 84: 678-685; Henney et al. (1991) Proc. Natl. Acad. Sci. USA 88: 8154-8158; And Senior et al. (1989) Am. Rev. Respir. Dis. 139: 1251-1256. The MMP Zn ²⁺ Zn ²⁺ with its catalytic domain - is dependent enzymes. Ca ²⁺ stabilizes the tertiary structure of MMP considerably [Lowry et al. (1992) Proteins 12: 42-48; And Lovejoy et al. (1994) Science 263: 375-377. Therefore, depending on similar metal dependencies, the TRRE may be part of the MMP family with 11 MMPs cloned.
Serine proteases as well as metallic proteases have been reported to be involved in the cleavage of TNF-R by simultaneously adding PMA and serine protease inhibitors to the culture medium of THP-1 cells. These results indicate that at least two different kinds of proteolytic enzymes are involved in the induction phase of TRRE, and these enzymes form a cascade for their activation. However, the results presented in this example show that serine protease inhibitors have no effect on partially-purified TRRE samples whose enzymatic activity has already been established [Bjornberg et al. (1995); And Hwang et al. (1993). This evidence suggests that TRRE may be a metallic protease and that serine proteases will act on the activation of TRRE. Most MMPs are actually secreted in the inactive soluble proenzyme form (Zymogen), which is proteolytically regulated by various serine proteases and autocatalytic mechanisms to become active forms [VanWart and Birkedal- Hansen (1990) Proc. Natl. Acad. Sci. USA 87: 5578-5582.
Human monocytes and macrophages are known to produce a variety of MMPs, but gelatinous, caseinic, elastinic, and type I collagen activity was not detected in crude and partially-purified TRRE.
The induction pattern of TRRE by PMA and known MMPs is quite different. To induce MMPs, monocyte U-937 cells, fibrosarcoma HT-1080 cells, or peritoneal exudate macrophages (PEM) should typically be stimulated with LPS or PMA for 1-3 days. On the other hand, compared to the induction of this extended period, TRRE is released very quickly into the culture supernatant 30 minutes after stimulation with PMA. As described in Example 2, TRRE is stored in cells very close to the cell membrane and is immediately secreted by PMA stimulation, and TRRE is also synthesized very quickly within 2 hours by PMA stimulation. Therefore, as determined from the zymography gel data and the different induction patterns by PMA, TRRE is one of the existing MMP families, despite its appearance regarding serine proteolytic enzymes involved in metal-request and its activation. It cannot be classified.
Soluble TNF-R is known to bind to TNF and LT and form a complex consisting of three sTNF-Rs and three TNFs or LTs (Banner et al. (1993)). According to the gel filtration analysis presented above, the profiles of TRRE and soluble p75 TNF-R were very similar, both peaking at approximately 150 kDa. Since the molecular weight of the soluble p75 TNF-R was reported to be 40 kDa, this suggests that sTNF-R exists as a complex formed with TRRE or TNF or otherwise as a single oligomer. The hypothesis that TRRE and sTNF-R form a complex in vitro was confirmed by the recovery of 25% TRRE activity from the soluble p75 TNF-R affinity column. This means that the free TRRE has the ability to bind its catalytic product, sTNF-R. The remaining 75% not bound to the affinity column may already be bound to sTNF-R or may not have sufficient affinity to bind to sTNF-R even though it is present in free form.
While it is believed that significant amounts of enzyme product (EP) complexes will be present in the reaction solution, TRRE retained 86% of activity even after one treatment with excess substrate, which makes it easier when the complex encounters a new substrate. It can be separated. This EP complex does not appear to significantly inhibit the enzymatic response of TRRE. Although sTNF-R is a potent inhibitor of the physiological activity of TNF and LT, sTNF-R has also been shown to play another role in stabilizing TNF activity in vitro [Aderka et al. (1992) J. Exp. Med. 175: 323-329. Therefore, sTNF-R will act as a stabilizer by modulating complex formation not only for TNF but also for TRRE. This EP complex between TRRE and sTNF-R will probably be formed under in vitro conditions, but it is possible for TRRE, sTNF-R and TNF to make several types of complexes in vitro as well as in vivo and therefore physiologically important. will be.
Example 5 Biological Effects of TRRE
In this example, the effects and biological significance of TRRE were studied, including (a) substrate specificity and (b) function in vitro.
Fluororesin isothiocyanate (FITC) -conjugated anti-CD54, FITC-conjugated goat anti-rabbit and mouse antibody, mouse monoclonal anti-CD30, anti-CD11b and anti-IL-1R (Serotec, Washington DC ) Was used in this study. Rabbit polyclonal anti-p55 and p75 TNF-R were constructed according to the method of Yamamoto et al. [Yamamoto et al. (1978) Cell Immunol. 38: 403-416. THP-1 cells were treated with 1,000 and / or 5,000 U / ml TRRE eluted from DEAE-Sephadex column for 30 minutes and in 1 × 10 ^{5 in a} 12 × 75 mm polystyrene tube (Fisher Scientific, Pittsburg, PA). Cells were transferred at a density of / 100 μl / tube. Cells were then pelleted by centrifugation at 350 × g for 5 minutes at 4 ° C. and directly with 10 μl of FITC-conjugated anti-CD54 (diluted in cold PBS / 0.5% sodium acid), Indirectly treated with mouse monoclonal anti-CD11b, IL-1R and CD30 followed by FITC-conjugated anti-mouse antibody, and also indirectly with rabbit polyclonal anti-p55 and p75 TNF-R and then FITC- Staining with conjugated anti-rabbit antibody.
THP-1 cells stained with the respective antibodies without TRRE treatment were used as negative controls. The tubes were incubated for 45 minutes at 4 ° C., stirred every 15 minutes, then washed twice with PBS / 2% FCS to repellet and then resuspended in 200 μl of 1% paraformaldehyde. These labeled THP-1 cells were analyzed using a fluorescein activated cell sorter (FACS) (Becton-Dickinson, San Jose, Calif.) Using a 15 mW argon laser excited at 488 nm. Fluorescent signals were based on aggregates resulting from light scattering and analysis of forward and right angles to remove dead cells. The indicated signal (10 ⁴ ) was detected in a 585 BP filter and analyzed using Lysis II software. The resulting values were expressed as a fraction of the positive cells, and the mean channel fluorescence intensity (MFI) of stained THP-1 cells treated with TRRE was converted into MFI of cells (negative control cells) not treated with TRRE. Calculated by dividing.
To test the in vitro TNF cell lysis assay by TRRE treatment, an L929 cell lysis assay was performed according to the method described by Katanaga et al. (Gatanaga et al. (1990b)). Briefly, L929 cells, a sticky murine fibroblast cell line, were plated overnight (70,000 cells / 0.1 ml / well in 96-well plates). Monolayered L929 cells were pretreated for 30 minutes with 100,500 or 2,500 U / ml of partially-purified TRRE and then exposed to serial dilutions of recombinant human TNF for 1 hour. After washing the plate with RPMI-1640 with 10% FCS to remove TRRE and TNF, cells were treated with RPMI- with 10% FCS containing 1 μg / ml actinomycin D for 18 hours. Incubated in 5% CO ₂ at 37 ° C. in 1640. The culture supernatant was then aspirated off and 50 μl of 1% crystal violet solution was added to each well. Plates were incubated for 15 minutes at room temperature. The plates were washed with tap water, then dried in air and the cells stained with crystal violet were lysed with 100 mM HCl in 100 μl of methanol per well. Absorbance at 550 nm was measured using an EAR 400 AT plate reader (SLT-Labinstruments, Salzburg, Austria).
TRRE was originally defined as a protease that cleaves overexpressed human p75 TNF-R on cDNA-transformed COS-1 cells (C75R). To study whether TRRE can cleave not only p75 but also p55 TNF-R on human cells, the expression of partially purified TRRE from human THP-1 cells at low levels of both p55 and p75 (Scatcher analysis) Approximately 1,500 receptors / cell, data not shown). The TRRE eluate obtained from the DEAE-Sephadex column was added to THP-1 cells (5 × 10 ⁶ cells / ml) for 30 minutes so that the final TRRE concentration was 1,000 U / ml. The concentrations of soluble p55 and p75 TNF-R in the supernatant were measured by soluble p55 and p75 TNF-R ELISA. TRRE was found to cleave both p55 and p75 TNF-R on THP-1 cells and release 2,382 and 1,662 pg / ml of soluble p55 and p75 TNF-R, respectively (FIG. 15). Therefore, TRRE was able to cleave both human p55 and p75 TNF-R on C75R cells on human p75 TNF-R and THP-1 cells.
As for the substrate specificity of TRRE, surface expression of p55 and p75 TNF-R, CD54, CD11b, IL-1R, and CD30 on THP-1 cells treated with TRRE, specific antibodies as described above for THP-1 cells The cells were labeled and then investigated by flow cytometry. After treatment of THP-1 cells with 5,000 U / ml of TRRE, expression of p55 and p75 TNF-R was reduced to 8% and 49% (% control), respectively (FIG. 14) and TRRE (1,000 and 5,000 U / Dose response to ml) was seen upon cleavage of p55 and p75 TNF-R. However, there was no significant change in the expression of CD54, CD11b, IL-1R and CD30 with or without TRRE treatment (5,000 U / ml) (FIG. 14). Of the receptors and antigens examined, TRRE was effective only against p55 and p75 TNF-R. The% control was obtained by dividing the mean channel fluorescence intensity (MFI) of stained THP-1 cells treated with TRRE by the MFI of cells (control) not treated with TRRE.
To study the in vitro biological significance of shedding sTNF-R by TRRE, an L929 lysis assay modified by including TRRE treatment was performed as described above. L929 cells without TRRE treatment were used as negative controls. L929 cells were pretreated for 30 minutes with 100,500 or 2,500 U / ml of TRRE obtained from DEAE-fractions and then exposed to serial dilutions of recombinant human TNF for 1 hour. Plates were washed with media to remove TRRE and TNF, cells were incubated in 1 μg / ml ActD, stained with crystal violet (live cells are stained blue), and their lysis was 550 nm. The absorbance at was analyzed by measuring. The result is shown in FIG. The proportion of non-TNF-stimulated cells of surviving L929 cells pretreated with 0 (negative control), 100, 500 and 2,500 U / ml TRRE and stimulated with 4 ng / ml TNF were 24%, respectively. 30%, 38%, and 74%. Therefore, TRRE-treated L929 cells were protected against TNF-induced lysis, and more importantly, a dose-response to this protection was detected.
Substrate-specificity of TRRE was investigated using membrane receptors and two non-TNF-R antigens. These receptors and antigens are expressed at sufficient levels on THP-1 cells and can be detected by FACS analysis, such as: (i) IL-1R, its soluble form is proteolytic It is known to be produced by cleavage; (ii) CD30 (ki-l), which belongs to the same receptor family as TNF-R (TNF-R / NGF-R superfamily), and its soluble form is probably produced by Zn ²⁺ -dependent metallic proteolytic enzymes do; (iii) CD54 (ICAMI), which belongs to the immunoglobulin superfamily of cohesive molecules comprising VCAM-1 and is known to have a soluble form; And (iv) CD11b, which belongs to the integrin family of sticky molecules and does not appear to have a soluble form. The FACS analysis provided above showed that TRRE was very specific only for cleavage of the two TNF-Rs and did not affect any other membrane receptors and antigens with soluble forms. In addition, the ability of TRRE to cleave two TNF-Rs was supported by the soluble p55 and p75 TNF-R ELISAs provided in this example.
TRRE down-regulated the expression of TNF-R on the cell surface of L929 cells in TNF binding assays. Pretreatment with TRRE protected L929 cells from the activity of killing cells of TNF. Therefore, TRRE has two methods; TNF activity can be modulated by reducing the number of TNF-Rs or generating sTNF-Rs that bind to and inactivate TNFs. Cleavage of TNF-R by TRRE will probably protect TNF-sensitive cells and organs in diseases associated with high levels of TNF. On the other hand, high serum levels of TNF and sTNF-R are sometimes associated with various types of cancer, while cleavage of TNF-R by TRRE can regulate cancer cells that are more resistant to the effects of TNF.
Example 6 Purification of TRRE
TRRE was purified by 100% saturated ammonium sulphate precipitation, DEAE-Sepadex chromatography, and natural PAGE to be apparently homogeneous. Partially-purified TRRE was fractionated by SDS-PAGE, resulting in several protein bands. Two protein bands shown at 60 kDa and 37 kDa were selected as possible TRRE candidates.
THP-1 cells were cultured in 8 roller bottles per formulation (Corning, Corning, NY). This contains 500 ml of 10% FCS-containing RPMI-1640 per roller bottle. Cells were collected for induction of TRRE when the cell density reached approximately 1 × 10 ⁶ to 1.5 × 10 ⁶ cells / ml. Cells were then incubated for 30 minutes in 1% FCS medium to which ^10-6 M of phorbol 12-myristate 13-acetate PMA (Sigma) was added and washed to obtain a sample without PMA. After washing with medium without serum, cells were incubated in medium containing 1% FCS for an additional 2 hours of PMA and the supernatant was collected as an enzyme source.
The cell free supernatant was concentrated by 100% saturated ammonium sulphate precipitation. All following procedures were carried out at 4 ° C. 69.7 g of solid ammonium sulfate per 100 ml were added to the collected supernatant with gentle gentle agitation over 4 hours and then stirred for an additional 1 hour. The precipitate was collected by centrifugation at 10,000 × g for 30 minutes, and it was redissolved in approximately twice the volume of PBS of the pellet. The redissolved precipitate was then dialyzed against 10 mM Tris-HCl, 60 mM NaCl, pH 7.0 buffer (buffer 1). The nominal molecular weight cut-off (NMWC) of the dialysis tube at this time was about 6,000 to 8,000 for 60 hours.
The concentrated sample was diluted in an equal volume of 50 mM Tris-HCl, 60 mM NaCl, pH 8.0 buffer (buffer 2), and then anion-exchange chromatography, already equilibrated with buffer 2, DEAE-Sepadex A -25 (Pharmacia Biotech, Uppsala, Sweden) (2.5 × 10 cm). After washing the column with 150 ml of Buffer 2, the sample was eluted with 60 mM (buffer 2) to 250 mM NaCl, 50 mM Tris-HCl, pH 8.0 linear ionic strength gradient (total volume; 250 ml). . The flow rate was 1 ml / min and a 4 ml fraction of Sample A and a 3 ml fraction of Sample B were collected. Each fraction was measured for absorbance at 280 nm and analyzed for TRRE activity. Several DEAE fractions showing the highest TRRE inactivity (highest TRRE unit / A280 value) were collected and subjected to further steps.
These active DEAE fractions were concentrated to approximately 500 μl by centrifugal force using Centripep-10 filter (10,000 MW cut-off membrane) (Amicon). This concentrated sample was then applied with cooling in several lanes of 6% polyacrylamide gel electrophoresis (PAGE) (15 × 10 cm) under non-denaturing natural conditions to provide biological activity of TRRE after separation by electrophoresis. Was recovered. One completed lane was cut vertically on the side of the native PAGE slab gel and stained using a silver staining kit (Bio-Rad). The remainder of the natural PAGE gel was then cut horizontally into 5 mm pieces and each piece was eluted with shaking at 4 ° C. overnight in 1 ml of PBS. Each eluate was analyzed for TRRE activity. The location of TRRE was confirmed by comparing the TRRE activity of each eluate with the protein bands of the silver-stained natural gel. Each TRRE active fraction eluted from the natural PAGE gel was then concentrated to approximately 50 μl by centrifugal force using a Microcon-10 filter (10,000 MW cut-off membrane) (Amicon). These concentrated samples were subjected to 8% SDS-PAGE under denaturing conditions and stained with Kumachi fluorescent blue R-250 (CBB). Stained gels were then used to determine whether there was a correlation between TRRE activity and the intensity of the protein bands.
PMA-stimulated THP-1 cells were prepared at a density of 1.5 × 10 ⁶ cells / ml using the original 4 L of THP-1 cell supernatant (8 roller bottles) representing one lot, TRRE sources (mean ± standard error) of 3,679 ± 144 ml and 3,623 ± 118 ml, respectively, were obtained for Sample A and Sample B. After precipitating with 100% saturated ammonium sulfate, Sample A and Sample B were dissolved in 49 ± 5 ml and 4.5 ± 1.1 ml of PBS, and dialyzed for 60 hours, respectively for 109 ± 12 ml and 24 hours for 13.2 ± 2.7 ml The final volume was reached. Final concentration folds of Sample A and Sample B were 34.2 ± 2.3 and 268 ± 26 times, respectively. Sample A contained 4,327 ± 1,150 U / ml of TRRE and total (15.9 ± 2.5) × 10 ⁶ U in the original supernatant. After 60 hours of dialysis, concentrated Sample A contained a TRRE of (12.1 ± 2.9) × 10 ⁴ U / ml and a total of (13.2 ± 2.1) × 10 ⁶ U. Therefore, in sample A, 81.6 ± 8.1% of TRRE was recovered by 100% saturated ammonium sulfate precipitation. In the case of Sample B, TRRE activity in the original supernatant could not be detected due to contamination of ^10-6 M PMA. After ammonium sulphate precipitation followed by intensive dialysis for 24 hours to remove ammonium sulphate and PMA, the concentrated sample B was (21.9 ± 2.1) × 10 ⁴ U / ml and the total (28.9 ± 3.8) × 10 ⁵ U TRRE was included, corresponding to 1/5 of the total TRRE of Sample A.
A lot of one of the dialysis samples A was loaded onto a 4 drop DEAE-Sepadex column. This column was used to elute protein and TRRE activity as a single broad peak of similar shape gradually decreasing in later fractions. The peak protein fraction (A280) and the TRRE active fraction are always Fr. 20 and Fr. It was found near 15 (Figure 16). Therefore, TRRE was eluted 4 or 5 fractions ahead of the major protein consisting predominantly bovine serum albumin (BSA). The concentration of the highest TRRE fraction was (25.5 ± 2.4) × 10 ³ U / ml. Using this column, 0.3 ± 0.2%, 4.5 ± 1.1%, and 35.1 ± 6.3%, respectively, during the flow passage, at the wash, and when compared to the original TRRE activity (100%) loaded on the column in all fractions. TRRE activity was recovered. Of the total protein recovered (100%), 21.8 ± 2.5%, 32.6 ± 2.8%, and 45.6 ± 5.3% of protein were obtained at the time of passage, washing, and in all fractions, respectively.
On the other hand, due to the extremely low amount of protein, two lots of Sample B were combined and loaded onto a DEAE-Sepadex column per column purification. TRRE activity eluted as a single broad peak as in Sample A (data not shown). However, elution of the protein was retained at low values once it reached a certain point, so no significant peak was detected. The peak of TRRE activity is Fr. 18, the protein was Fr. The highest value gradually reached near 40. Using this column, the TRRE activity of 0 ± 0%, 2.2 ± 0.4%, and 11.2 ± 1.3% compared to the original TRRE activity (100%) loaded on the column at the time of flow, washing, and all Recovered from fractions. 9.5 ± 3.7%, 42.4 ± 5.5%, and 48.1 ± 6.1% of the total protein recovered (100%) were located at the time of passage, during washing, and in all fractions, which were similar to the fraction of sample A . However, the efficiency of TRRE recovered from Sample B was lower than Sample A.
Several DEAE fractions with the highest relative TRRE activity were concentrated and loaded on native PAGE. TRRE activity of Sample A was detected in four fractions (fragments) from Fr.8 to Fr.11 on native PAGE. The highest TRRE activity was Fr. At 9 or 10, which included (9.3 ± 1.6) × 10 ³ U / ml activity, and the total recovered TRRE activity through concentrated and native PAGE was 16.2 ± 4.1%. The highest TRRE fraction was found in a tight group of several bands detected by silver staining of the native PAGE gel. On the other hand, TRRE activity of Sample B was determined by Fr. It was detected in three fractions from 13 to 15. The recovery of TRRE activity from these three fractions was 8.7 ± 1.0% through concentrated and native PAGE. Only two or three silver-stained protein bands were present in the Fr. Detected at 13-15.
SDS-PAGE of the active eluate concentrated from the native PAGE showed that there were several protein bands in Sample B. The highest activity TRRE eluate showed a protein band at approximately 120 kDa, 60 kDa and 37 kDa, while several other TRRE-active eluates showed 70 kDa, including 120 kDa, 60 kDa and 37 kDa bands. Protein bands were shown at 55 kDa, 40 kDa and 20 kDa. More bands were detected in Sample A because of the protein contaminated from FCS. The intensity of the protein bands of TRRE should be related to TRRE activity. Therefore, the 60 kDa and 37 kDa bands were considered the strongest TRRE candidates because their intensity correspondingly increased as the TRRE levels were higher. The 37 kDa band was considered to correlate more with the TRRE than the 60 kDa band.
Two types of enzyme sources of TRRE were prepared for its purification. First, in Sample A, TRRE was induced at high levels from THP-1 cells stimulated with PMA in 1% FCS-containing medium without PMA. This is a good source of TRRE, but it has been observed that many proteins are contaminated from FCS. In a second source, named Sample B, TRRE was derived much less than from Sample A from THP-1 cells in PMA-containing medium without FCS. Here a very pure protein sample without FCS-contamination was obtained, but a much smaller amount of TRRE activity was detected. Moreover, the recovery of TRRE activity in Sample B was significantly less than in Sample A at all stages of the purification process, including dialysis, centrifugation concentration by membrane-filter, DEAE-column and native PAGE. Therefore, insufficient amount of purified TRRE was isolated for AA sequencing in the course of Sample B. However, sample B helped to identify possible TRRE bands in the final stage of SDS-PAGE because of their purity. Therefore, after identifying potential bands from purer sample B in SDS-PAGE, a sufficient amount of purified TRRE was prepared for AA sequencing using sample A.
In DEAE-Sepadex column chromatography, TRRE eluted before the main protein, most of which was considered BSA. Since DEAE-Sepadex also has a gel-filtration effect in addition to the anion-exchange effect, the molecular size of TRRE can be larger than BSA with a molecular size of about 69 kDa. However, the discovery that the molecular size of possible TRRE posteriors in the final purification step was 37 kDa and 60 kDa with 371 Tg of trypsin (Boehringer) also showed TRRE showing the ability to bind sTNF-R in Example 3 Will support the data presented in this example indicating that is present as a complex formed with sTNF-R and TNF. Another possibility is that TRRE may exist as a single or hetero oligomer, presumably consisting of 37 kDa and / or 60 kDa monomers.
In this example, TRRE has been shown to readily lose its activity through all purification steps, especially at low protein and salt concentrations. We performed several different purification procedures in addition to those described in this example. For example, C4 reversed phase high performance liquid chromatography (HPLC) was performed on a TRRE sample with a 5 to 95% gradient of acetonitrile with moderate solubility. However, TRRE activity was completely inactivated in acetonitrile, although a small amount of activity was restored after lyophilization. Rapid protein liquid chromatography (FPLC) was then applied, which proved inadequate for separating TRRE from major proteins or for large scale purification. To specifically purify TRRE, we performed two types of affinity chromatography, the soluble p75 TNF-R affinity column and the anti-soluble p75 TNF-R antibody affinity column mentioned in Example 3. Was attempted by taking advantage of the ability to form complexes with sTNF-R. These methods were possible to obtain pure TRRE, but were inadequate to handle the bulk required for AA sequencing. In view of all these factors, our purification scheme worked very effectively to recover very specific TRRE activity and could handle large and large volumes of protein samples required for AA sequencing.
Example 7 Purification of TRRE
The following protocol was used for purification of TRRE.
1. Supernatant from large cell culture of THP-1 stimulated with 10 ^-6 M PMA
↓
2. Ammonium Sulphate Precipitation
↓
3. DEAE- Sephadex Chromatography
↓
4. 6% NATURAL PAGE
↓
5. 10% SDS-PAGE
↓
6. Transfer to Nitrocellulose Membrane
↓
7. Trypsin digestion
↓
8. Reversed Phase HPLC C18 Columns
↓
9. Analysis of Amino Acid Sequences.
Step 1: Large Scale Cell Culture. THP-1 was incubated in a 4.0 L serum-containing medium until the cell density reached 1 × 10 ⁶ to 1.5 × 10 ⁶ cells / ml. Cells were incubated for 30 minutes in 1% FCS containing medium with ^10-6 M of PMA (Porbol 12-myristate 13-acetate) (Sigma Chemical, St. Louis, Mo.). After washing in medium without serum, cells were further incubated in 4 L of 1% FCS containing medium without PMA for 2 hours and the supernatant collected as an enzyme source.
Step 2: Ammonium Sulphate Precipitation. The supernatant was concentrated by the 100% ammonium sulphate precipitation method described in Example 4. The precipitate was collected and redissolved in PBS and dialyzed against 10 mM Tris-HCl, 60 mM NaCl, pH 7.0 for 60 hours.
Step 3: DEAE-Sepadex Chromatography. The concentrated sample was diluted with an equal volume of 50 mM Tris-HCl, 60 mM NaCl (pH 8.0) and subjected to anion-exchange chromatography, DEAE-Sepadex A-25 (Pharmacia Biotech, Uppsala, Sweden) column It was. Samples were eluted with a sodium linear gradient (60 mM to 250 mM NaCl). Several fractions containing the most specific TRRE activity were collected.
Step 4: Natural PAGE. Active DEAE fractions were concentrated to 500 Tl by centrifugal force using Centriprep-10 filter (10,000 MW cut-off membrane) (Amicon). This concentrated sample was subjected to 6% PAGE under non-denaturing natural conditions. The gel was cut into 5 mm pieces horizontally so that each was eluted into 1 ml of PBS. Each TRRE active fraction was concentrated to 50 Tl by centrifugal force using Centriprep-10 filter.
Step 5: SDS-PAGE and Protein Blotting. The concentrated active sample eluted from the native PAGE was loaded onto 10% SDS-PAGE. The protein was then transferred to the nitrocellulose membrane by electrophoresis and stained with 0.1% Ponceau S.
Step 6: Preparation of Peptide Fragments for Microsequencing. Each band was cut from the nitrocellulose membrane and overnight with 1 Tg of trypsin (Boehringer) in digestion buffer (0.1 M Tris-HCl, pH 8.0, 1 mM CaCl ₂ , 10% (v / v) acetonitrile). Digested.
The digested sample was spun and the resulting supernatant was injected into a reversed phase HPLC C ₁₈ column (4.6 × 250 mm). Peptide fragments were eluted using a linear gradient of 0-60% acetonitrile containing 0.1% trifluoroacetic acid. Several peak fractions were collected and analyzed for amino acid sequences using peptide sequencers from Applied Biosystems, Inc.
Candidate for TRRE.
SDS-PAGE of the concentrated active eluate obtained from the native PAGE showed several protein bands. The TRRE eluate containing the highest activity showed a protein band at approximately 120 kDa, 60 kDa, and 37 kDa. The 60 kDa and 37 kDa bands were the strongest candidates as TRRE because their corresponding intensities increased with increasing TRRE activity levels. Therefore, the 60 kDa band (p60) of the blotting membrane initially stained with 0.1% Ponceau S was cut and used for further analysis.
Example 8 Use of TRRE Used for Septic Shock
To test the effect of TRRE on preventing mortality in test animals treated with lipopolysaccharide (LPS) to induce sepsis and septic shock. The following protocol was performed.
In general, mice were injected with lethal or subfatal amounts of LPS, followed by control buffer or TRRE. Peripheral blood samples were then collected at intervals to establish whether TRRE blocks TNF-induced production of other cytokines in the bloodstream. Animals were evaluated as a whole for the ability of TRRE to block the clinical effects of shock, and then euthanized and tissue examined by histopathological methods.
More specifically, mature Balb / c mice, a traditional animal model for septic shock studies [Mack et al. (1997) J. Surg. Res. 69: 399-407; And Seljelid et al. (1997) Scand. J. Immunol. 45: 683-687] was placed in a restriction device and 0.1 ml of a solution containing 10 ng to 10 mg of LPS in phosphate buffered saline (PBS) was injected intravenously through the tail vein. These levels of LPS induce shocks ranging from moderate to fatal in mice of the strain. Shocks result from changes in vascular permeability, fluid loss, and dehydration and are sometimes accompanied by syndromes including narcolepsy, bent stop position, crumpled hair, interruption of food and drink, cyanosis, and in severe cases death within 12 to 24 hours. Control mice were injected with PBS. Different amounts (2,000 or 4,000 U) of purified human TRRE were injected IV in a volume of 0.1 ml within 1 hour before or after LPS injection. 30 minutes, 60 minutes, and 90 minutes after injection of LPS, serum (0.1 ml) was collected from the tail vein using a 27 gauge needle and 1 ml IV syringe. This serum was treated with heparin and stored frozen at -20 ° C. Samples from a number of experiments were tested by ELISA for the presence of sTNF-R, TNF, IL-8, and IL-6. Animals were monitored for the clinical effect of shock over the next 12 hours. Selected animals were euthanized 3 to 12 hours after treatment, carcasses were dissected, various organs and tissues fixed in formalin, inserted in paraffin, dissected and stained with hematoxylin-eosin (H and E). Tissue fragments were subjected to histopathological and immunopathological investigations.
As can be seen in FIG. 19, mice injected with LPS alone or LPS and control buffer were found to die rapidly. 50% of test animals died after 8 hours (LPS) or 9 hours (LPS and control buffer) and all animals died after 15 hours. In contrast, when LPS was injected with a 2,000 U TRRE, mortality was delayed and mortality was low. Only 40% of the animals died after 24 hours. When 4,000 U of TRRE was injected with LPS, all animals were alive for 24 hours. Therefore, TRRE can prevent death induced by LPS in test animals.
Example 9 Effect of TRRE on Necrosis Activity of Human TNF in Vivo
The following protocol was performed to test the effect of TRRE on tumor necrosis in test animals in which tumors were generated and TNF continued to be injected.
In general, on day 0, 15 BALB / c mice were injected intradermal with 2 × 20 ⁵ Meth A tumor cells to produce Meth A tumors of the skin on the abdominal wall of the mice.
On day 7, mice were divided into three groups of 5 animals each as follows:
Group 1: Intravenous injection with TNF (1 μg / mouse).
Group 2: Intravenously injected with TNF (1 μg / mouse) and intratumorally with TRRE (400 units / mouse 6, 12 hours after TNF injection).
Group 3: intravenous injection with TNF (1 μg / mouse) and intratumoral injection with control medium (400 units / mouse 6, 12 hours after TNF injection).
On day 8, tumor necrosis was measured and the following results were obtained:
% Necrosis
Group 1: 100 (5/5)
Second group: 20 (1/5)
Third group: 80 (4/5)
Therefore, injecting TRRE significantly reduced the ability of TNF to induce necrosis of Meth A tumors in BALB / c mice.
Although the foregoing description has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be appreciated by those skilled in the art that any variation or modification may be made. Therefore, the description and examples should not be construed as limiting the scope of the invention as outlined by the appended claims.

权利要求:
Claims (62)
[1" claim-type="Currently amended] A composition comprising substantially purified protein having enzymatic activity to release tumor necrosis factor receptor (TNF-R) and having a natural form with an apparent molecular weight of about 120 kD.
[2" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of D-L-N-L-G-A-Q-A-T-I-T-N-L-P (SEQ ID NO: 1).
[3" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of G-L-D-E-T-Q-N-L-I-T-V-P-Y (SEQ ID NO: 2) or S-E-R-W-P-Q-M-A-N-K-V-S-R (SEQ ID NO: 3).
[4" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of I-V-V-T-K (SEQ ID NO: 4).
[5" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of E-F-P-H / S-P-V-D-A-A-T-R (SEQ ID NO: 5).
[6" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of A-L-F-E-L-I-Y-E-L-L-L / E-A-Y-I-I / N-V-L (SEQ ID NO: 6).
[7" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of L-D-Y-Q-E / T-S-Y-S-A-A-V-A-R (SEQ ID NO: 7).
[8" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of L-A-L-Q / I-E-S-P-S / P (SEQ ID NO: 8).
[9" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of L-F-L-K-N-T-G-L-A-R (SEQ ID NO: 9).
[10" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of M-A-L-Q-K-G-D-R (SEQ ID NO: 10).
[11" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of K-L-L-E-L-N-V-V-A (SEQ ID NO: 11).
[12" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of V / I-T-D-M-V-V-G-I-X-G (SEQ ID NO: 12) (X is an unidentified amino acid residue).
[13" claim-type="Currently amended] The composition of claim 1, wherein the protein further comprises an internal amino acid sequence of L-V-D-Y-D-X-L-F-Q-N-L (SEQ ID NO: 13) or K-E-A-L-I-A-K-I-R (SEQ ID NO: 14).
[14" claim-type="Currently amended] The composition of claim 1, wherein the enzymatic activity of the protein is not inhibited by a serine protease inhibitor or a cysteine protease inhibitor.
[15" claim-type="Currently amended] The composition of claim 1, wherein the enzymatic activity of the protein is inhibited by a metalloprotease inhibitor.
[16" claim-type="Currently amended] The composition of claim 1, further comprising a physiologically acceptable buffer.
[17" claim-type="Currently amended] 17. The composition of claim 16, wherein the physiologically acceptable buffer is selected from the group consisting of saline and phosphate buffered saline.
[18" claim-type="Currently amended] A composition comprising a substantially purified antibody or antibody binding fragment specific for a protein according to claim 1.
[19" claim-type="Currently amended] The antibody of claim 18, wherein the antibody or antibody binding fragment is a whole natural polyclonal antibody, a whole natural monoclonal antibody, a bispecific antibody, a chimeric antibody, a Fab, F (ab ′) 2, a single chain variable region fragment, a fusion polypeptide. And a humanized antibody.
[20" claim-type="Currently amended] A method of treating a disease associated with alterations in the level or activity of tumor necrosis factor, characterized by administering an amount of the protein according to claim 1 sufficient to indirectly reduce the level of tumor necrosis factor.
[21" claim-type="Currently amended] The method of claim 20, wherein the disease is an inflammatory disease.
[22" claim-type="Currently amended] 21. The method of claim 20, wherein the disease is selected from the group consisting of autoimmune disease, endotoxin shock, rheumatoid arthritis, trauma, infection, and multiple sclerosis.
[23" claim-type="Currently amended] 21. The method of claim 20, wherein the method of administration is selected from the group consisting of topical, parenteral, subcutaneous, intramuscular, intraperitoneal, intraluminal, intrathecal, and intravenous methods.
[24" claim-type="Currently amended] A method for measuring the activity of a protein according to claim 1,
a) obtaining cells (TNF-R-cells) that do not express significant amounts of TNF-R;
b) manipulating the cells to express recombinant TNF-R (TNF-R + cells);
c) incubating TNF-R + cells with TRRE and appropriate medium;
d) measuring the amount of soluble TNF-R released from step c);
e) incubating the TNF-R + cells with the medium of step c);
f) measuring the amount of soluble TNF-R released from step e);
g) incubating the TNF-R- cells with the medium of step c);
h) measuring the amount of soluble TNF-R released from step g); And
i) subtracting the amount of soluble TNF-R obtained in step h) from the amount obtained in step f) to obtain a background amount and subtracting the amount from the amount obtained in step d)
Method comprising the.
[25" claim-type="Currently amended] A method of diagnosing a disease associated with a change in the level or activity of a protein according to claim 1, comprising: obtaining a biological sample from a patient; Measuring the activity of the protein in the sample; And comparing the activity with that of the control biological sample.
[26" claim-type="Currently amended] The method of claim 25, wherein the disease is cancer.
[27" claim-type="Currently amended] The method of claim 25, wherein the cancer is selected from the group consisting of glioblastoma, melanoma, neuroblastoma, adenocarcinoma, soft tissue sarcoma, leukemia, lymphoma and carcinoma.
[28" claim-type="Currently amended] 28. The method of claim 27, wherein the cancer is a carcinoma, astrocytoma, oligodendroma, epidermoid tumor, medulloblastoma, primitive neuroectodermal tumor, pancreatic ductal adenocarcinoma, small cell and large cell pulmonary adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, epithelial adenocarcinoma and its Liver metastasis, liver cancer, cholangiocarcinoma, duct and lobules adenocarcinoma, squamous and adenocarcinoma of the cervix, epithelial carcinoma of the uterus and ovary, prostate adenocarcinoma, transitional squamous cell bladder carcinoma, B and T cell lymphoma (lobe and diffuse), Plasmacytoma, acute and chronic leukemia, malignant melanoma, soft tissue sarcoma and leiomyoma.
[29" claim-type="Currently amended] A method for treating a disease associated with elevated levels of soluble tumor necrosis factor receptor, characterized by administering an amount of an inhibitor of tumor necrosis factor receptor releasing enzyme in an amount effective to reduce the level of soluble tumor necrosis factor receptor.
[30" claim-type="Currently amended] 30. The method of claim 29, wherein the disease is cancer.
[31" claim-type="Currently amended] 31. The method of claim 30, wherein the cancer is astrocytoma, oligodendroma, epithelial cell tumor, medulloblastoma, primitive ectoectoderm tumor, pancreatic adenocarcinoma, small cell and large cell lung adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, epithelial adenocarcinoma and liver metastases thereof. , Liver cancer, cholangiocarcinoma, duct and lobules adenocarcinoma, squamous and adenocarcinoma of the cervix, epithelial carcinoma of the uterus and ovary, prostate adenocarcinoma, transitional squamous bladder carcinoma, B and T cell lymphoma (lobe and diffuse), plasmacytoma, Acute and chronic leukemia, malignant melanoma, soft tissue sarcoma and leiomyoma.
[32" claim-type="Currently amended] The method of claim 29, wherein the inhibitor encodes a metalloprotease inhibitor, an antibody that blocks the effective interaction between tumor necrosis factor receptor and tumor necrosis factor receptor release enzyme, a polynucleotide encoding the antibody, a tumor necrosis factor receptor release enzyme And antisense oligonucleotides specific for the gene, and ribozymes specific for the gene encoding the tumor necrosis factor receptor releasing enzyme.
[33" claim-type="Currently amended] 32. The method of claim 30, further comprising administering at least one amount of cytokine effective to enhance an immune response against cancer.
[34" claim-type="Currently amended] 34. The method of claim 33, wherein the cytokine is selected from the group consisting of tumor necrosis factor, interleukin 2, interleukin 4, granulocyte macrophage colony stimulating factor, and granulocyte colony stimulating factor.
[35" claim-type="Currently amended] 32. The method of claim 30, further comprising administering a chemotherapeutic agent.
[36" claim-type="Currently amended] 36. The chemotherapeutic agent of claim 35, wherein the chemotherapeutic agent is a radioisotope, vinca alkaloid, adriamycin, bleomycin sulfate, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, duanorubicin hydrochloride. , Doxorubicin hydrochloride, etoposide, fluorouracil, romastin, mechlororetamine hydrochloride, melphalan, mercaptopurine, methotrexate, mitomycin, mitotan, pentostatin, pipeobroman, procarbaz hydrochloride, streptozo And toxin, taxol, thioguanine, and uracil mustard.
[37" claim-type="Currently amended] A composition comprising substantially purified protein having enzymatic activity to release tumor necrosis factor receptor (TNF-R) and having a natural form with an apparent molecular weight of about 60 kD.
[38" claim-type="Currently amended] The composition of claim 37, wherein the protein further comprises an internal amino acid sequence of D-L-N-L-G-A-Q-A-T-I / L-T-N-L-P (SEQ ID NO: 15).
[39" claim-type="Currently amended] The composition of claim 37, wherein said protein further comprises an internal amino acid sequence of L-A-E-D-Y-L-S-G / L-W-L-E / G-R (SEQ ID NO: 16).
[40" claim-type="Currently amended] The composition of claim 37, wherein the protein further comprises an internal amino acid sequence of L / K-V / L-D / E-Y-D / E-X-L / F-F-Q-N-L (SEQ ID NO: 17) (X is an unidentified amino acid residue).
[41" claim-type="Currently amended] 38. The composition of claim 37, wherein the enzymatic activity of the protein is inhibited by a metalloprotease inhibitor.
[42" claim-type="Currently amended] 38. The composition of claim 37, further comprising a physiologically acceptable buffer.
[43" claim-type="Currently amended] 43. The composition of claim 42, wherein the physiologically acceptable buffer is selected from the group consisting of saline and phosphate buffered saline.
[44" claim-type="Currently amended] A composition comprising a substantially purified antibody binding fragment specific for a protein according to claim 37.
[45" claim-type="Currently amended] 45. The antibody of claim 44, wherein the antibody binding fragment is a whole natural polyclonal antibody, a whole natural monoclonal antibody, a bispecific antibody, a chimeric antibody, a Fab, a F (ab ') 2, a single chain variable region fragment, a fusion polypeptide and a humanized Composition selected from the group consisting of antibodies.
[46" claim-type="Currently amended] A method of treating a disease associated with elevated levels of tumor necrosis factor, characterized by administering a protein according to claim 37 in an amount sufficient to indirectly reduce the level of tumor necrosis factor.
[47" claim-type="Currently amended] 47. The method of claim 46, wherein the disease is an inflammatory disease.
[48" claim-type="Currently amended] 47. The method of claim 46, wherein the disease is selected from the group consisting of autoimmune disease, endotoxin shock, rheumatoid arthritis, trauma, infection, and multiple sclerosis.
[49" claim-type="Currently amended] 47. The method of claim 46, wherein the method of administration is selected from the group consisting of topical, parenteral, subcutaneous, intramuscular, intraperitoneal, intraluminal, intrathecal, and intravenous methods.
[50" claim-type="Currently amended] A method for measuring the activity of a protein according to claim 37,
a) obtaining cells (TNF-R-cells) that do not express significant amounts of TNF-R;
b) manipulating the cells to express recombinant TNF-R (TNF-R + cells);
c) incubating TNF-R + cells with TRRE and appropriate medium;
d) measuring the amount of soluble TNF-R released from step c);
e) incubating the TNF-R + cells with the medium of step c);
f) measuring the amount of soluble TNF-R released from step e);
g) incubating the TNF-R- cells with the medium of step c);
h) measuring the amount of soluble TNF-R released from step g); And
i) subtracting the amount of soluble TNF-R obtained in step h) from the amount obtained in step f) to obtain a background amount and subtracting the amount from the amount obtained in step d)
Method comprising the.
[51" claim-type="Currently amended] 38. A method of diagnosing a disease associated with elevated levels of a protein according to claim 37, comprising: obtaining a biological sample from a patient; Measuring the activity of the protein in the sample; And comparing the activity with that of the control biological sample.
[52" claim-type="Currently amended] The method of claim 51, wherein the disease is cancer.
[53" claim-type="Currently amended] 52. The method of claim 51, wherein the cancer is selected from the group consisting of glioblastoma, melanoma, neuroblastoma, adenocarcinoma, soft tissue sarcoma, leukemia, lymphoma and carcinoma.
[54" claim-type="Currently amended] 54. The method of claim 53, wherein the cancer is a carcinoma, astrocytoma, oligodendroma, epithelial cell tumor, medulloblastoma, primitive neuroectodermal tumor, pancreatic ductal adenocarcinoma, small cell and large cell lung adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, epithelial adenocarcinoma and its Liver metastasis, liver cancer, cholangiocarcinoma, duct and lobules adenocarcinoma, squamous and adenocarcinoma of the cervix, epithelial carcinoma of the uterus and ovary, prostate adenocarcinoma, transitional squamous cell bladder carcinoma, B and T cell lymphoma (lobe and diffuse), Plasmacytoma, acute and chronic leukemia, malignant melanoma, soft tissue sarcoma and leiomyoma.
[55" claim-type="Currently amended] A method for treating a disease associated with elevated levels of soluble tumor necrosis factor receptor, characterized by administering an amount of an inhibitor of tumor necrosis factor receptor releasing enzyme in an amount effective to reduce the level of soluble tumor necrosis factor receptor.
[56" claim-type="Currently amended] 56. The method of claim 55, wherein the disease is cancer.
[57" claim-type="Currently amended] 59. The method of claim 56, wherein the cancer is astrocytoma, oligodendroma, epithelial cell tumor, medulloblastoma, primitive ectoectoderm tumor, pancreatic adenocarcinoma, small cell and large cell lung adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, epithelial adenocarcinoma and liver metastases thereof. , Liver cancer, cholangiocarcinoma, duct and lobules adenocarcinoma, squamous and adenocarcinoma of the cervix, epithelial carcinoma of the uterus and ovary, prostate adenocarcinoma, transitional squamous bladder carcinoma, B and T cell lymphoma (lobe and diffuse), plasmacytoma, Acute and chronic leukemia, malignant melanoma, soft tissue sarcoma and leiomyoma.
[58" claim-type="Currently amended] The antisense oligonucleotide of claim 55, wherein the inhibitor is a metalloprotease inhibitor, an antibody that blocks the effective interaction between tumor necrosis factor receptor and tumor necrosis factor receptor release enzyme, a gene specific for a gene encoding tumor necrosis factor receptor release enzyme. And ribozymes specific for genes encoding tumor necrosis factor receptor release enzymes.
[59" claim-type="Currently amended] 59. The method of claim 56, further comprising administering at least one amount of cytokine effective to enhance an immune response against cancer.
[60" claim-type="Currently amended] 60. The method of claim 59, wherein the cytokine is selected from the group consisting of tumor necrosis factor, interleukin 2, interleukin 4, granulocyte macrophage colony stimulating factor, and granulocyte colony stimulating factor.
[61" claim-type="Currently amended] 59. The method of claim 56, further comprising administering a chemotherapeutic agent.
[62" claim-type="Currently amended] 64. The chemotherapeutic agent of claim 61, wherein the chemotherapeutic agent is a radioisotope, vinca alkaloid, adriamycin, bleomycin sulfate, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, duanorubicin hydrochloride. , Doxorubicin hydrochloride, etoposide, fluorouracil, romastin, mechlororetamine hydrochloride, melphalan, mercaptopurine, methotrexate, mitomycin, mitotan, pentostatin, pipeobroman, procarbaz hydrochloride, streptozo And toxin, taxol, thioguanine, and uracil mustard.

类似技术:

---

公开号 | 公开日 | 专利标题

---

Hasturk et al.2012|Oral inflammatory diseases and systemic inflammation: role of the macrophage

---

Peske et al.2015|Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment

---

Schumacher et al.2015|Shedding of endogenous interleukin-6 receptor | is governed by a disintegrin and metalloproteinase | proteases while a full-length IL-6R isoform localizes to circulating microvesicles

---

US10494416B2|2019-12-03|Methods of modulating immune responses using BCMA polypeptide

---

Jones et al.2011|Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

---

Yap et al.2010|Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances

---

Arduise et al.2008|Tetraspanins regulate ADAM10-mediated cleavage of TNF-α and epidermal growth factor

---

Kong et al.2000|Osteoprotegerin ligand: a regulator of immune responses and bone physiology

---

Suh et al.2002|Mechanisms of constitutive NF‐κB activation in human prostate cancer cells

---

Fridman et al.2011|Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation

---

Hong et al.2007|Interleukin‐6 and its receptor in cancer: implications for translational therapeutics

---

Foa et al.1990|Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease

---

Li et al.2003|The TNF-α transgenic mouse model of inflammatory arthritis

---

Schulte et al.2007|ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death

---

Rincón et al.1997|Interleukin |-6 directs the differentiation of IL-4–producing CD4+ T cells

---

Deiss et al.1996|Cathepsin D protease mediates programmed cell death induced by interferon‐gamma, Fas/APO‐1 and TNF‐alpha.

---

Kataoka2005|The caspase-8 modulator c-FLIP

---

Decoster et al.1995|Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor

---

Ding et al.1989|Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide.

---

Murphy et al.2008|Clipping, shedding and RIPping keep immunity on cue

---

Beliën et al.1999|Membrane-type 1 matrix metalloprotease | enables invasive migration of glioma cells in central nervous system white matter

---

Rose-John2013|ADAM17, shedding, TACE as therapeutic targets

---

Almasan et al.2003|Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

---

Beutler et al.1988|The common mediator of shock, cachexia, and tumor necrosis

---

JP2506340B2|1996-06-12|Pharmaceutical composition

同族专利:

---

公开号 | 公开日

---

CA2270898A1|1998-05-14|

---

JP2001508648A|2001-07-03|

---

US6858402B2|2005-02-22|

---

US6569664B1|2003-05-27|

---

KR100533531B1|2005-12-06|

---

NZ335864A|2001-09-28|

---

ID22049A|1999-08-26|

---

BR9712900A|2000-11-28|

---

IL129787D0|2000-02-29|

---

NO992187D0|1999-05-05|

---

EP0938548A1|1999-09-01|

---

AT403714T|2008-08-15|

---

DE69738887D1|2008-09-18|

---

US6573062B1|2003-06-03|

---

AU744873B2|2002-03-07|

---

US20030170776A1|2003-09-11|

---

NO992187L|1999-07-01|

---

EP0938548B1|2008-08-06|

---

WO1998020140A1|1998-05-14|

---

AU5162198A|1998-05-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1996-11-06|Priority to US3076196P

---

1996-11-06|Priority to US60/030,761

---

1997-11-05|Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아

---

2000-08-25|Publication of KR20000053073A

---

2005-12-06|Application granted

---

2005-12-06|Publication of KR100533531B1

优先权:

---

申请号 | 申请日 | 专利标题

---

US3076196P| true| 1996-11-06|1996-11-06|

---

US60/030,761|1996-11-06|